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Abstract  
Chronic obstruction pulmonary disease (COPD) is a major cause of morbidity and mortality 
across the world.  COPD is currently the fourth leading cause of death in the world and is 
predicted to become the third leading cause of chronic illness and death worldwide by 2030. 
There are several therapeutic strategies to reduce COPD symptoms and complications such as; 
bronchodilator medications, antibiotics, inhaled corticosteroids and rehabilitation. However, 
none of the available pharmacological or non-pharmacological treatments for COPD have been 
shown to delay or correct long-term defects in lung function. Small nucleic acids such as non-
coding RNA (ncRNA) and interference microRNA (miRNA) have recently gained attention as 
a new class of therapeutics for various genetic diseases. Modulation of miRNA expression and 
function represents a promising strategy for therapeutic intervention in disorders such as 
inflammatory lung disease including COPD. In this study the aim was to design, formulate and 
characterise polymeric nanoparticles (NPs) containing miR-146a. This was followed by spray-
dying using L-leucine and mannitol to prepare dry powder nanocomposite microparticles 
(NCMPs) for pulmonary delivery.  
Anionic and cationic poly (glycerol adipate-co- ω-pentadecalactone), (PGA-co-PDL), NPs 
were produced using poly (vinyl alcohol) and dioleoyltrimethylammoniumpropane (DOTAP) 
respectively. The particle size of the anionic NPs was 266.10±20.80 nm and the incorporation 
of DOTAP resulted in NPs of 244.80±4.40 nm at 15 % DOTAP concentration. The zeta 
potential (ZP) of 15 % DOTAP NPs was +14.8±0.26 mV. Fluorescently labelled synthetic 
miRNA (miR-146a) was adsorbed onto the surface of the optimum 15 % DOTAP NPs. The 
cell viability studies indicated that over 65 % of A549 cells remained viable after 24 h exposure 
to cationic NPs at a concentration of 1.25 mg/ml.  
 xvi 
 
The spray drying process was optimised to produce NCMPs with recovered NPs of 
409.7±10.05 nm, yield of 86.05±15.01 % and low moisture content 2.02±0.03 %. The NCMPs 
produced had a spherical shape and corrugated surface. The in vitro aerosolisation analysis 
showed a mass mean aerodynamic diameters (MMAD) of less than 6 µm indicating the NCMPs 
would be deposited in the middle to deep lung region and a fine particle fraction (FPF) of 
51.33±2.90 %.  Internalisation of miR-146a loaded cationic NPs was observed in A549 cell 
lines using both fluorescence and confocal microscopy.  
The miR146a delivered to A549 cells as miR-146a-NPs and miR146a-NCMPs had a dose 
dependent reduction on target gene repression; interleukin 1 receptor-associated kinase 
(IRAK1) expression to 40 % and TNF receptor-associated factor (TRAF6) expression to over 
20 %. Moreover, the miR-146a biological activity was maintained after spray drying. These 
findings demonstrate the promise of miR-146a-NPs/NCMPs as a dry powder pulmonary for 
the treatment of COPD, protecting miR-146a from degradation and enzymatic activity in the 
lung airways.  
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1 General introduction  
1.1 Pulmonary disease; COPD  
Lung inflammation is a common symptom in various lung diseases, which can be either acute 
or chronic in nature. For example, pneumonia is an acute inflammatory disease, whereas 
chronic lung diseases include asthma, cystic fibrosis and chronic obstruction pulmonary 
disease (COPD). COPD is a heterogeneous inflammatory disease characterised by airflow 
limitation, narrowing of the small airways and destruction of alveoli walls, which is considered 
a hallmark of emphysema (Cosio et al. 2009). An additional feature is chronic bronchitis which 
is associated with mucus and inflammation of the airways (Cosio et al. 2009). In a healthy lung, 
when a person inhales and exhales, each air sac fills up and deflates with air and the airflow 
passes through the lung airway smoothly (Fig 1–1). Whereas, in a lung afflicted with COPD, 
there will be less air flow in and out of the airways due to; the air sacs and airways having lost 
their elastic quality, destruction of the walls between air sacs, the walls of airways become 
thick and inflamed, and there is a greater presence of mucus than usual which can prevent air 
entering and leaving the lung (Pauwels et al. 2001).   One of the mechanisms that affect COPD 
pathogenesis is that alveolar epithelial cells start looking fibroblastic, due to epithelial-
mesenchymal transition (Nishioka et al. 2015). 
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Figure 1 – 1. Illustrative diagram of a healthy normal and COPD lung airways. In a 
healthy lung, during inhalation and exhalation airflow passes through the lung airway 
smoothly, whereas, a lung afflicted with COPD, there will be less air flow in and out of 
the airways.  
  
 
1.2 Statistics for COPD  
COPD is a major cause of morbidity and high mortality rates throughout the world.  COPD is 
currently the fourth leading cause of death in the world and is predicted to become the third 
leading cause of chronic illness and death worldwide by 2030 (World Health statistics 2008). 
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The World Health Organization (WHO) estimated that 251 million people were affected by 
COPD in 2016, and the Global Initiative on Obstructive Lung Disease (GOLD) indicated the 
disease is more prevalent among males than females (Global Strategy for the Diagnosis, 
Management and Prevention of COPD and GOLD 2016). A study among participants in 
developed countries found that a healthy male at 40 years of age has a 12.7 % chance of 
contracting COPD in the next forty years of his life, whereas for a healthy female the 
corresponding probability is 8.3 %  (Halbert et al. 2006).  Moreover, similar data in low middle 
income counties indicated almost a quarter of adults aged over 40 years were diagnosed with 
mild airflow obstruction, defined as a reduced post-bronchodilator ratio of  forced expiratory 
volume in 1 second (FEV1) to  forced vital capacity (FVC) (Halbert et al. 2006). Thus, the 
incidence of COPD occurs in both genders and in both developed and low middle income 
countries which indicates the marked global burden of this disease (Afonso et al. 2011).  
1.3 COPD inflammatory causes   
Primarily, COPD is contracted as a consequence of tobacco smoking, which progressively 
damages the lungs through nicotine and tar deposition, consequently leading to airflow 
constriction. Despite smoking being a major risk factor for COPD, only 20 % of smokers 
develop this pathology (Pauwels and Rabe 2004). Bronchial epithelial cells are the first 
anatomical barrier to noxious cigarette smoke particles and are involved in the initiation of 
airway remodelling through the production of proinflammatory mediators (Jeffery 2004).  
The exposure to cigarette smoke releases pro-inflammatory mediators, cytokines, which leads 
to the release of proteases and high oxidant concentrations that damage lung tissue (Heijink et 
al. 2013). Other factors such as exposure to indoor and outdoor air pollutants, bacterial 
infections, occupational hazards and genetic abnormalities contribute towards emphysema in 
the form of alpha-1-antitrypsin (A1AT) deficiency, have also been implicated in the 
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pathogenies of COPD ( (Mannino and Buist 2007). There is also a relationship between 
exposure to indoor biomass fuels and a number of respiratory diseases including COPD (Ezzati 
2005, Orozco-Levi et al. 2006), particularly in low middle income countries that rely on 
biomass fuels as source of everyday domestic energy (Umoh and Peters 2014). The smoke 
released from burning biomass fuels releases toxic substances, and causes extremely high 
levels of air pollution that affects and irritate the respiratory system. Desalu et al. showed the 
increased risk of respiratory symptoms and chronic bronchitis in women using biomass fuels 
in Nigeria  (Desalu et al. 2010). Various studies have revealed that biomass fuel smoke is one 
of the causes of obstructive airway diseases (van Gemert et al. 2011, Oluwole et al. 2013, Zhou 
et al. 2014).  
1.4 Current treatment  
There are several clinically appropriate therapeutic strategies to reduce COPD symptoms and 
frequency for example, bronchodilator medications which are used to reduce bronchial spasms, 
antibiotics to reduce respiratory infections, inhaled corticosteroids which are recommended for 
reducing inflammation, as well as influenza and pneumococcal vaccines to reduce serious 
illness and death. There is also rehabilitation available to reduce symptoms and enhance quality 
of life and oxygen can be administered to keep mucous membranes moist and provide adequate 
hydration. However, none of these pharmacological and non-pharmacological treatments for 
COPD have been shown to delay and correct the long-term defects in lung function (Global 
Strategy for the Diagnosis, Management and Prevention of COPD and GOLD 2016).  
In parallel to inflammatory and pro-inflammatory mediators involved in COPD pathogenesis, 
micro RNA (miRNAs) have recently been attributed to the pathogenesis of COPD (Angulo et 
al. 2012). miRNAs are endogenous and noncoding functional mediators of RNA interference 
(RNAi). They are an essential group of 18-25 single strand nucleotides (Bartel 2004). Almost 
 5 | P a g e  
 
2,000 human miRNAs that have been discovered, despite some of their biological functions 
being unknown (Li and Belmonte 2015). The first miRNA (Lin-4) for cellular development 
was discovered in 1993 in Caenor-habditis elegans (Lee et al. 1993). Later, Reinhart et al. 
discovered let-7 and its association with cellular development timing (Reinhart et al. 2000). 
The following year Hutvágner et al. performed a similar study which indicated the relationship 
between let-7 and development regulation timing in both humans and animals (Hutvágner et 
al. 2001). The role of these miRNAs is in the post-transcriptional regulation of gene expression 
by binding to targeting messenger RNA (mRNA), promoting translation repression and 
mediating a cleavage and degradation of the mRNA target, and consequently blocking the 
translation of mRNAs into proteins  (Tomankova et al. 2010).  
1.5 Biogenesis of miRNA 
miRNA genes are generally found in intergenic areas, and they tend to be highly concentrated 
in the vicinity of the centromere of each chromosome (Meurant 2012). There are thousands of 
miRNAs that have been identified in various organisms and have been added to miRNA 
databases e.g miRBase (www.miRBase.org), which is a centralized repository for miRNAs and 
miRNA annotation. For example, the hsa-miR-146a entry into miRBase, has a chromosome 
where it is located and the loss of the function of miR-146 leads to an individual suffering from 
chromosome 5q deletion syndrome (Fig. 1–2).  
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Figure 1 – 2. Example miRNA entry in miRBase, hsa-miR-146 from human genome 
(http://www.mirbase.org/). The mature miRNAs derived from the 5’ and 3’ arms are in 
pink, corresponding to miR-145a-5p and miR-146a-3p. The miR-146 mimic used 
throughout this project corresponds to miR-146a-5p. 
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miRNA is transcribed in the nucleus by RNA polymerase II, to produce miRNA primary 
transcripts (pri-miRNAs). The pri-miRNA is cleaved by Drosha which partners with RNA-
binding protein DGRC8 forming pre-miRNA which is then exported to the cytoplasm by 
Exportin-5. In the cytoplasm, the pre-miRNA is cleaved by RNAase type III Dicer to produce 
21-23 nucleotides  long, with two nucleotide 3’ overhanging, called a miRNA/miRNA* duplex. 
This duplex is subsequently incorporated in a RNA-induced Silencing Complex (RISC), which 
contains Argonaute protein (Fig 1–3).  
1.5.1 The RISC Complex 
There are four Argonaute (AGO) proteins that represent a key component of RISC, which 
contains two domains; PIWI and PAZ. PIWI structurally resembles RNaseH, which is essential 
for target cleavage,  and PAZ, recognizes the miRNA 3’ end  (Kuhn and Joshua-Tor 2013). 
Nevertheless, AGO protein is loaded with double stranded miRNA precursors that form the 
RISC loading complex, and forms a passenger strand (miR*) that is degraded. A guide strand 
(miR) then guides the miRNA:AGO protein complex to the target 3’ untranslated region (UTR) 
of mRNA and promotes mRNA transitional inhibition or degradation depending on the 
complementarity between miRNA seed  and 3’UTRs (Brodersen and Voinnet 2009, Rajewsky 
2006, Elkayam et al. 2012, Schirle et al. 2014).  
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Figure 1 – 3. Schematic overview of miRNA biogenesis (adapted from (Winter et al. 2009). 
miRNA biogenesis starts with transcription of miRNA gene by RNA polymerase II to pri-
miRNAs. The pri-miRNA cleaved by Drosha which partners with RNA-binding protein 
DGRC8 forming pre-miRNA. The pre-miRNA is exported to cytoplasm by Exportin-5, 
which cleaved by RNAase type III Dicer in cytoplasm to produce 21-23 nucleotides   long, 
with two nucleotide 3’ overhanging, called a miRNA/miRNA* duplex. This duplex 
incorporated in RISC which contain AGO proteins which forms a passenger strand 
(miR*) that is degraded and a guide strand (miR) that target 3’ untranslated region 
(UTR) of mRNA and promotes mRNA transitional repression. 
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1.6 miRNA as a biomarker for COPD  
miRNAs play an important role in the regulation of gene expression for various normal and 
pathological mechanisms. Hence miRNAs are good candidates to act as potential biomarker 
agents in diagnostic and therapeutic clinics.  
Studies have detected miRNAs in various body fluids, tissue and cell types in both animal 
models and humans, and their involvement in lung development and progression, indicates 
their significant role in inflammatory responses (Fig.  1–4), (Akbas et al. 2012).  These studies 
have shown the presence of miRNA in lung tissue and bodily fluids such as sputum, plasma 
and urine. The stability of miRNAs in sputum and plasma varies with the level of degradative 
enzymes in blood, which reflects the biological importance of miRNA. Chen et al.  found that  
miRNAs levels  in serum are stable and consistent among individuals (Chen et al. 2008).  Akbas 
et al. showed that miR-7 was up-regulated whereas another four miRNAs (miR-20a, -28-
3p,34c-5p, and 100) were down-regulated when comparing COPD patients with a control 
population (Akbas et al. 2012). Similarly a study by Perry et al. showed that the changes in 
expression of miR-146a could regulate the inflammatory response in human alveolar epithelial 
lung cells  (Perry et al. 2008). Therefore, with the presence and stability of miRNA, it is 
possible to differentiate between healthy individuals with healthy lung tissue and those 
suffering from lung inflammation by using miRNA as a diagnostic and therapeutic biomarker.  
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Figure 1–4. Illustration of the main miRNAs involved in COPD. Orange boxes show up-
regulated miRNAs (cell, tissue and body fluids). Blue boxes indicate down-regulated 
miRNAs (cell, tissue and body fluids).   
 
1.7 Role of miRNA in inflammatory response  
In the relationship between miRNA and the inflammatory response in COPD, miR-146a is 
precisely linked to COPD pathogenesis. Sato et al. demonstrated that miR-146a and the down-
regulation involved in pathogenesis increases the abnormal inflammatory cyclooxygenase 
(COX-2) half-life in COPD and enhances production of prostaglandin E2. These expressed 
proteins are considered a hallmark of chronic inflammation in COPD (Sato et al. 2010). These 
findings were evaluated through in vitro studies using a miR-146a mimic and Western Blot 
analysis to determine COX-2 protein expression in cytokine-treated COPD fibroblasts. A 
Quantitative Real- Time Polymerase Chain Reaction (qRT-PCR) assay  was used to quantify 
miR-146a expression and the luciferase reporter assay demonstrated a binding of miR146a to 
COX-2 mRNA  3’UTR  (Sato et al. 2010).  
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miR-146a was shown to be involved in the targeting of interleukin-1 and Toll-like receptor 
(TLR) signalling, of which NF-кB activation is a primary downstream effector, known as 
interleukin 1 receptor-associated kinase (IRAK1) and TNF receptor-associated factor 
(TRAF6). Taganov et al. reported  miR-146a base-pairs with sequences in the 3’ UTRs of 
IRAK1 and TRAF6, and that these UTRs inhibit expression of a linked reporter gene. miR-
146a is capable of controlling TLR and cytokine signalling through negative feedback 
regulation, associating down regulation of IRAK1 and TRAF6 protein levels (Taganov et al. 
2006, Nahid et al. 2009).  Moreover, miR-146a plays a crucial role in the negative feedback 
regulation of interleukins,  IRAK1 and TRAF6  (Fig. 1–5)  (Bhaumik et al. 2009). In addition, 
there are various genes associated with inflammation of COPD airways including intercellular 
adhesion molecules (ICAM)-1 (Papi and Johnston 1999), tumour necrosis factor TNF-α 
(Leeper-Woodford and Detmer 1999),  monocyte chemoattractant  MCP-1 (Ueda et al. 1997), 
endothelin-1 (Quehenberger et al. 2000), and secretory leucocyte proteinase inhibitor   
(Sallenave et al. 1997).  
There are also other miRNAs present, which are not directly related to the inflammatory 
response of COPD. Guo et al. used a murine model to evaluate miR-125b which caused a 
significant reduction in neutrophil counts and pro-inflammatory cytokines corresponding with 
lipopolysaccharide (LPS) induced pulmonary inflammation (Guo et al. 2014). The LPS was 
targeted through the myeloid differentiation factor 88 (My88), which showed the capability of 
miR-203 to regulate inflammation (Wei et al. 2013). In addition, other miRNAs involved in 
COPD inflammation include miR-150, miR-181a and miR-20a.  These were down regulated 
in COPD compared to non-COPD models in vitro and in vivo (Manoharan et al. 2014, Xie et 
al. 2014). Manoharan et al. found that an increase of miR-150 levels correlated with reduced 
chemokine CXCL 1 expression in mice (Manoharan et al. 2014). A study by Xie et al. used 
qRT-PCR to measure expressed miR- 21 and miR-181a levels in enforced smoking rat models 
 12 | P a g e  
 
to predict the occurrence of COPD. They demonstrated that levels of miR-21 were significantly 
higher, whereas levels of miR-181a were significantly lower, in COPD patients than in healthy 
control subjects. This suggests that levels of miR-21 and miR-181a can be useful for predicting 
the development of COPD in heavy smokers  (Xie et al. 2014). 
 
Figure 1–5. The role of miR-146a in TLR4 and IL-1R mediated signal transduction 
(adapted from (Oglesby et al. 2010, Bhoj and Chen 2009). The TLR4 and IL-1R signalling 
is started after binding with adaptor protein MyD88 which in turn recruits IRAK4 leads 
to activation of IRAK1 and TRAF6. This activates the protein kinases TAK1 and IKK 
complexes as a result allowing NF-кB starts transcriptional regulation and produce pro-
inflammatory cytokines.  miR-146a downregulates IRAK1 and TRAF6 protein levels and 
leads to a change in signalling pathway.  
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1.8 miRNA as a therapeutic agent 
The ability of miRNAs to concurrently target multiple genes involved in inflammatory 
pathways is an advantage over siRNAs, which typically target a single gene transcript 
(Pasquinelli et al. 2005, Rossi 2009) and  miRNAs can also be used  therapeutically to target 
multiple cell types and multiple inflammatory processes  (Conde et al. 2016). For this reason, 
the study of miRNAs may potentially generate new therapies for targeting and treating COPD 
rather than symptomatic relief.  
miRNA replacement therapy can be administered using two distinct approaches. The first 
method, involves introducing double-stranded synthetic mimic miRNA known as anti-miRs. 
These mimics are complementary to the miRNAs of interest and following uptake by cells they 
bind to RISC in the cytoplasm (Bader et al. 2010)  restoring the loss of miRNA function due 
to down expression. This method is more specific for restoring miRNA function, as it is 
associated with decreased off target effect and offers the ability of personalization according 
to the miRNA required, and has less side effects compared to miRNA antagonists (Bader et al. 
2010).  The significant therapeutic action of miRNA mimics enabled miR-34 to be used for the 
treatment of many cancers such as;  colon, ovarian, cervical, non-small cell lung cancer, and 
hepatocellular carcinoma, and miR-34 has been tested in phase I clinical trials (Bouchie 
2013b).  
The second method is known as the miRNA-expression vector where oligonucleotide miRNA 
mimics are combined with a vector. The viral vectors have been employed to deliver let-7 to 
decrease lung tumour and breast cancer cells (Esquela-Kerscher et al. 2008, Yu et al. 2007). 
Moreover, Trang et al. demonstrated the use of a neutral lipid emulsion delivery system of both 
miRNA-34a and let-7 mimics in a xenograft model to reduce tumour growth (Trang et al. 
2011). The use of these mimics has also been explored in lung cancer; Wu et al. therapeutically 
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delivered miR-29b in cationic lipoplexes for lung cancer in both in vitro using A549 cell lines 
and in vivo (Wu et al. 2013c).  This suggests that miRNA mimics could also be successful in 
COPD therapeutics. Although COPD alveolar epithelial cells undergo a epithelial-
mesenchymal transition, miRNA mimics can target this transition and restore their function 
(Nishioka et al. 2015).  
miRNA replacement therapy is considered an attractive target for clinical therapeutic 
development and there are various miRNAs currently in pre-clinical and clinical trials. The 
success of these clinical trials is crucial for the development of strategies for miRNA therapies. 
Pre-clinical studies using miR-34 for hepatocellular carcinoma and lung cancer progressed, in 
2013, to the clinical trial stage where MRX34 was the first miRNA replacement therapy in 
clinical trials (Bouchie 2013a). MRX34 development from the biopharmaceutical company  
Mirna Therapeutics, has completed phase I and the study is ongoing in terms safety, 
pharmacokinetics and pharmacodynamics (Beg et al. 2015).  
1.9 Delivery of miRNA to the lung  
When developing pulmonary delivery systems, it is important to consider the unique 
anatomical and physiological characteristics of the lung. The lung has a large alveolar surface 
area (80 sq. m) and offers a controlled low enzyme environment, ideal for the systemic 
absorption of macromolecules promoting efficient local and systemic delivery of drugs 
(Muralidharan et al. 2014). The lung is divided into two main parts; the central and peripheral 
regions. The former includes the trachea, bronchi and bronchioles, which act as defence 
mechanisms against airborne particles, and these particles are cleared by cilia within the mucus 
layer that lines the epithelia. The peripheral region, contains alveolar sacs whose primary 
function is to enable the lung to perform  gas exchange during the breathing process (Ong et 
al. 2013).  
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When air is inhaled through the nose and mouth it passes through the larynx and trachea, which 
represent generation zero of the airways, proceeding until the sixteenth generations where the 
central bronchi and bronchioles end.  At the beginning of the seventeenth generation of 
bronchioles, the alveoli start to appear which contain the alveoli ducts (20th generation) and 
alveoli sacs end at the 23rd generation of Weibel model (Fig 1–6)  (Effros 2006). The Weibel 
airway model of human lung refers to upper and lower airways regions with respect to 
deposition of inhaled particles of different size  (Weibel 1963).  
The deposition of inhaled particles into the epithelial and alveolar regions or cells of the lung 
is influenced by various parameters such as particle size and shape, airway dimension, flow 
dynamic, breathing rate, respiratory volume and health of the individual. Particle deposition 
occurs through one of the following mechanisms; impaction, sedimentation, interception or 
diffusion (Heyder 2004) and is dependent on the aerodynamic diameter (da). The aerodynamic 
diameter is defined as the diameter of a sphere of a given geometric diameter, which is 
equivalent to the settling velocity of the particle in question and represented by the following 
equation:   
𝑑𝑎 = 𝑑𝑔 √
𝑝
𝑋. 𝑝𝑜
 
da  is the aerodynamic diameter, dg is geometric diameter, p is the particle density, reference 
density (usually from water) and   x is shape factor  (Bailey and Berkland 2009, Carvalho et al. 
2011b).  The inhaled particles would target lung epithelial and alveolar cells.    
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Figure 1–6. Diagram of human lung and deposition of inhaled particles dependent on 
particles size (adapted from (Kunda et al. 2013).  
 
 
Numerous delivery routes for small nucleic acids have been reported, ranging from local 
injection (ophthalmic drops, intradermal injection and intranasal spray) into target tissue to 
systemic applications (intravenous injection), (Fujita et al. 2013). Let-7 miRNA has previously 
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been delivered locally to the mouse lungs by intra-tumour injection into lung cancer tumours 
in vivo in order to improve bio-distribution (Trang et al. 2010). However, this resulted in 
limitations and challenges such as peripheral tumour cells remaining present and relative 
knockdown of let-7 targets by immunohistochemistry (Trang et al. 2010). Nevertheless, each 
route of administration has different pharmacological effects. The pulmonary delivery of small 
nucleic acids e.g siRNA to treat lung disease, asthma and cystic fibrosis, showed significant 
advantages when compared with local injection delivery (Valle et al. 2007, Labiris and 
Dolovich 2003a). ZaBeCor Pharmaceuticals have developed an inhaled siRNA for local 
delivery via the lungs to treat asthma and  phase I clinical trials showed 75 % of patients who 
received the treatment experienced less laboured breathing (Watts and Corey 2010, Xie and 
Merkel 2015). The pulmonary delivery of nucleic acids to the lung is non-invasive and offers 
various advantages over the other non-parenteral oral, buccal, transdermal and nasal routes 
(Table 1–1).  Although much research has been conducted on siRNA there is a limited amount 
of studies that have investigated the inhalation of miRNA. 
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Table 1– 1. Advantages and disadvantages of different routes of delivery of small nucleic acids therapeutics  
Route of 
administration 
Nucleic acid   
 
Advantages Disadvantages 
 
Reference 
 
Pulmonary  
 
siRNA  
 
 
 
 
 
 
 
 
(a) Nucleic acid can be administered in a 
reduced dose thereby decreasing local and 
systemic side effects.   
(b) Rapid clinical response due to locally 
targeting lung cells. 
(c) Avoiding degradation in serum due to 
lower nuclease activity in the airways. 
 Limited lung 
deposition depending 
upon carrier, 
formulation and device.  
 
a-(Patton and Byron 
2007) (Labiris and 
Dolovich 2003a) 
 
b- (Agu et al. 2001) 
 
c- (Takei et al. 2004) 
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Dry powder inhalation   siRNA (d) Higher pharmacokinetics, which in 
association with higher retention time can 
achieve the maximal therapeutic. 
(e) Bypass of the first hepatic metabolism 
Stability of siRNA 
associated with high 
temperature conditions 
and final powder loss in 
spray drying.  
(Jensen et al. 2010) and 
(Jensen et al. 2012) 
 
Intratumoural Injection 
   
Let-7 miRNA  Strong inhibition of tumour distribution Limited gene knock 
down.   
 
(Wiggins et al. 2010) 
miR-34a Clinical trial data showed ability to block 
lung tumour growth.  
None  
 
 
(Bouchie 2013a) 
Intravenous 
(systemically) 
 
 
siRNA  
 
Improved siRNA bio-distribution.  Accumulation in organs 
such as kidney and 
liver.  
(Braasch et al. 2004) and 
(Santel et al. 2006) 
miR-200c Improved radio-sensitivity. None (Cortez et al. 2014) 
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Intraocular  siRNA Reduction in inflammatory cells of 50%.  Invasive, and requires 
specialists such as 
clinicians.  
(Hérard et al. 2006) 
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1.10 Nanocarriers for miRNA delivery 
The delivery of miRNA to a site of action is a major challenge especially in diseased lungs, for 
the development of miRNA therapeutic. The physicochemical properties, such as 
hydrophilicity and negative charge,  make it difficult for these molecules to cross biological 
barriers (Yin et al. 2014). Viral vectors such as lentiviral (Liu et al. 2012, Lian et al. 2012)  and 
adenoviral (Xia et al. 2012, Gu et al. 2013)   vectors  have been used as carriers for the delivery 
of RNAs but they are known to cause immunologic inflammatory responses (Wang et al. 
2012b).  
 During the last few years, there has been a growing interest in nanotechnology for drug 
delivery. Components of living cells are commonly nano-sized, for example membrane 
transporters, ribosomes and receptors (Labhasetwar 2005) so nanoparticles (NPs), defined as 
small particles ranging from 1 to 1000 nm in diameter (Sung et al. 2007), can readily interact 
with intracellular and extracellular components of cells (Borm et al. 2006). NPs  loaded with 
therapeutic agents can be utilised as a drug delivery system (DDS) for systemic and local 
delivery to treat diseases (Labiris and Dolovich 2003b). Inhalation is a favourable non-invasive 
route for lung targeting, providing high bioavailability (Cefalu 2004). Therefore, using NPs is 
an interesting delivery strategy for small nucleic acids to treat respiratory diseases. 
Advantages of inhaled NPs 
NPs have several properties which make them good candidates for nucleic acid delivery, for 
example; the small particle size and positively charged surface. These properties allow the NPs 
to interact with cells, enhance intracellular uptake and release of miRNA to achieve the 
required gene silencing (Anwer et al. 2000, Stuart et al. 2006).  The lung has barriers such as 
lung lining fluid, epithelial cells and enzymes e.g endonucleases. Inhaled miRNA may be 
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degraded by these barriers. NPs, due to their size 200 nm, have the ability to diffuse through 
lining fluid. A study by Patton et al. showed the uptake of smaller particles 200 – 500 nm size 
could efficiently cross the lung barriers  (Patton et al. 2004).  
The surface of NPs can be modified with other molecules and functional groups and can be 
complexed with proteins, carbohydrate and antibodies (Davies et al. 2008). This can  enhance 
NP miRNA delivery  and cellular uptake compared to that of naked miRNA  (Yuba et al. 2008). 
Yin et al. showed the attachment of polyethylene glycol (PEG) to NPs protected nucleic acids 
from degradation and provided greater serum stability (Yin et al. 2014). miRNA complexed 
with cationic NPs protected against degradation, improved circulation and used in treatment of 
pulmonary disease such as cystic fibrosis (Yin et al. 2014, Konstan et al. 2004). Similarly, N-
[(1-(2,3-dioleyloxy)propyl)]-N-N-Ntrimethylammonium chloride (DOTMA), in combination 
with a lipid, formed a complex with plasmid DNA (Anwer et al. 2000).   
As a DDS to treat severe lung disease, poly (D L-lactide-co-glycolide acid), (PLGA), NPs with 
surface coated DOTAP were loaded with siRNA and incorporated into inhalable carrier 
particles by spray drying. The siRNA loaded NPs had a particle size of 216.0±6.0 nm and 
surface charge of +33.1±2.2 mV.  In vitro assays showed reduced gene expression and gene 
silencing of 73 % was achieved (Jensen et al. 2012) indicating that small nucleic acid-loaded 
NPs within a microcarrier can be used efficiently as a DDS in a pulmonary delivery platform 
to enable targeting of lung disease.  
1.11 Polymer based Nanoparticles 
In the last few years, several in vitro and in vivo studies have described different NP DDS used 
in gene delivery including lipid, inorganic materials and polymers (Table 1–2) and some that 
have included delivery technologies using non-viral carriers for appropriate safe delivery of 
miRNAs for different diseases (Fortunato et al. 2014).  
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Table 1– 2: Examples of nanocarriers used for gene delivery  
Type of NPs  Oligonucleotide Disease type  Particle 
size (nm)  
Reference  
 
 
 
Polymer based NPs 
 
 
Polyethylene-imine (PEI) miR-145 and miR-33a Colon cancer N/A (Ibrahim et al. 2011)  
Chitosan siRNA Lung cancer 40-600 (Howard et al. 2006a) 
poly(lactic-co-glycolic 
acid)- Polyethylene-imine 
(PLGA-PEI) 
miR-26a Liver cancer 
 
60 (Liang et al. 2011) 
Dendrimers 
(Poly amidoamine) 
miR-21 Glioblastoma <100 
 
 (Ren et al. 2010) 
 
 
 
Inorganic NPs  
Gold  miR-205 and miR-20a  Prostate Cancer  13 (Hao et al. 2011) 
Quantum dots  miR-491 Breast cancer 10 (Yoon et al. 2010) 
Silicon oxide DNA  Ovary  50 (Liu et al. 2009) 
Iron oxide  siRNA Cancer  15 (Lee et al. 2009) 
Lipid based NPs Cationic lipids  miR-107 Head and neck 
cancer 
150.1 
 
(Piao et al. 2012) 
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1.12  Nanoparticle surface charge and adsorption 
 Treatment of various diseases face hurdles for the efficient delivery of drugs necessary to 
alleviate the associated symptoms and/or eradication such as  cellular uptake, degradation and 
the ability to target specific cells (Pack et al. 2005). A great deal of interest has been shown in 
the viability of NPs for gene delivery and specific cell targeting (Green et al. 2007). However, 
uncoated NPs result in poor bio-compatibility and bio-distribution.  
The physicochemical characteristics of NPs such as the electrostatic charge on their surface 
affects interactions between the particles and the cell’s surface. The modification of NPs’ 
surfaces was shown to have an effect on particle uptake and bio-distribution. Moradi et al. 
modified NPs surface by adsorption of ligand which affects the level of cell internalisation and 
enhanced the NPs cellular uptake (Moradi et al. 2012). Polycationic  NPs with hydrophilic 
polymers containing amine groups, interacted with negatively charged phosphate groups of 
nucleic acids led to neutralisation and increase in bio-distribution (Hwang and Davis 2001) 
(Garnett 1999).  
 Coating NPs with lecithin and albumin can improve cellular uptake due to the electrostatic 
charge, where the positively charged particles bind to a negatively charged membrane and 
undergo endocytosis.  Zeta Potential is considered as an important property in measuring the 
particle surface that helps in particle adsorption, cell interaction and delivery. The electrical 
potential and surrounding surface charge prevents aggregation of NPs (Somasundaran et al. 
2004).  
Nucleic acids can bind and adsorb onto the cationic NPs via electrostatic interactions. Studies 
revealed that additionally attaching molecules such as chitosan, polyethylene-imine (PEI) or 
cationic lipids such as dioleoyltrimethylammonium propane (DOTAP) promote siRNA 
transfection efficacy. These cationic additives can be added to the NPs’ surface pre or post 
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formation. DOTAP has been successfully used for the modification of single-walled carbon 
nanotubes surfaces which lead to efficient small nucleic acid loading which improved cellular 
interactions (Li et al. 2014) and formed lipoplexes with negatively charged small nucleic acids 
when used for siRNA delivery in vitro  (Taetz et al. 2009). The NPs surface modification lead 
to high efficiency accompanied with safe siRNA delivery (Yezhelyev et al. 2008). At LJMU 
we have been investigating adsorption of macromolecules onto polymer based NPs to maintain 
stability and structural activity. An example is PGA-co-PDL NPs adsorbed  bovine serum 
albumin (BSA) onto the surface as proof of successful protein  adsorption  for subsequent 
development as a NP vaccine delivery system (Kunda et al. 2014b).  The coating of NPs with 
macromolecules can control many features such as release rate, cytotoxicity and cellular uptake 
(Yogasundaram et al. 2012).  In fact, the small nucleic acids adsorption on NPs provided an 
effective potential DDS as incorporating siRNA during the chemical synthesis of siRNA-
conjugated NPs may affect small nucleic acid integrity.  The siRNA must remain as a duplex 
to bind to RISC and cause gene silencing (Fire et al. 1998). However, other methods that added 
siRNA directly during synthesis lead to siRNA being affected by high temperature, and strong 
solvents resulting in the loss of function  (Soutschek et al. 2004).   
1.13 Dry powder microcarriers  
Inhaled NPs in the dry powder form smaller than 1 µm (diameter) are not capable of reaching 
the alveolar part of the lung and are likely to be exhaled during inspiration. However,  particles 
larger than 10 µm in diameter are most likely to deposit on  the throat tissue and sediment in 
upper lung mucus  (Heyder et al. 1986). Therefore, the ideal particle size for optimal particle 
deposition in the deep lung ranges from between 1 to 5 µm in diameter (Sakagami 2006). Due 
to these limitations, the NPs required for cellular uptake cannot be aerosolised effectively. 
Hence, NPs require formulation within an aerosolisable micron-sized carrier for efficient 
pulmonary delivery.  
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Spray drying can be used to formulate NPs and naked drugs into micro-sized dry powders 
providing a  mechanism for delivery to the lung via dry powder inhalation (DPI) (Jensen et al. 
2012).  There are three different types of inhalation devices available for pulmonary delivery; 
nebulizers, pressured metered dose inhalers (MDI) and dry powder inhalers (DPIs).  DPIs are 
the most common and offer advantages such as; overcoming issues with solubility, 
bioavailability, and stability, compared to other inhalation modes. Spray-drying parameters can 
be optimised to achieve microparticles with a desirable particle size, particle size distribution 
and aerosolisation properties suitable for pulmonary delivery  (Shoyele and Cawthorne 2006).  
1.13.1 Dry powder inhalers in gene delivery 
Carrier particles containing polymeric NPs have been used to deliver pDNA to the lung. 
Incorporating NPs (mean diameter 100–250 nm) containing pDNA into mannitol 
microparticles was successfully achieved by Takashima et al. and subsequently delivered to 
the bronchial and alveoli segments of the lung using DPI (Takashima et al. 2007).  Spray drying 
of small nucleic acids also showed potential for inhalation (Jensen et al. 2010). Nanocomposite 
microparticles (NCMPs) of PLGA nanospheres containing siRNA were formed by Ditte Marie 
et al. using a variety of excipients including trehalose, mannitol and lactose. The PLGA-siRNA 
NPs were spray dried producing dry powders of low moisture content and a desired inhalable 
aerodynamic particle size for inhalation. Importantly, the siRNA remained biologically active 
(Jensen et al. 2010).  
1.14 Dry powder preparation techniques 
There are several approaches to producing dry powders e.g freeze drying (Abdelwahed et al. 
2006), spray drying (Pilcer and Amighi 2010), spray freeze drying (Shoyele and Cawthorne 
2006) and super critical fluid techniques (Johnson 1997, Kaialy and Nokhodchi 2015, M Al-
fagih et al. 2011).  These methods can be optimised to  provide desirable attributes such as 
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narrow particle size distribution, improved dispensability, enhanced drug stability, optimised 
bioavailability and controlled release (Kunda et al. 2013, Kunda et al. 2015b), The different  
techniques can be  compared in terms of cost, yield, powder particle size and morphology 
(Table 1–3). To date, there are no studies reporting the use of these dry powder techniques with 
miRNA. However, some studies reported using these techniques on other nucleic acids such as 
siRNA (YT Chow and KW Lam 2015) suggesting formulated miRNA will be suitable for 
inhalation.   
1.14.1 Spray drying 
Spray-drying is a one-step drying technique in which dry powder can be produced by 
converting the liquid solution to dry powder through mixing the evaporated liquid with a drying 
hot gas medium. The spray-drying technique has four distinct stages; atomisation, spray air 
contact, drying and separation  (Pilcer and Amighi 2010). The advantage of this technique 
compared with the milling process, is the ability to generate higher respirable particles with a 
spherical shape in terms of decreasing drug and carrier adhesive forces, and more particle size 
distribution homogeneity (Steckel and Brandes 2004). All these characteristics have an effect 
on particle deposition, particle adhesion and drug delivery in respiratory airways. Such 
properties can be achieved by controlling spray-drying parameters such as solvent composition, 
coating excipients, drying and gas feed rate, solute concentration, liquid viscosity, solution feed 
rate and humidity (Johnson 1997).  
Another advantage with this technique is the propensity for laboratory-scale work and the 
higher drug loading ability (Peltonen et al. 2010). Spray drying using different carriers has been 
used widely for the preparation inhalable dry powders for delivering peptides, proteins, genes, 
and small nucleic acid delivery. Jensen et al.  used mannitol as an excipient to prepare dry 
powders containing PLGA NPs  loaded with siRNA to target lung disease (Jensen et al. 2012). 
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The study found that these dry powders released siRNA to lung tissue but didn't alter the gene 
silencing activity. This may be due to the thermal and mechanical stresses during the 
manufacturing process, which may affect the nucleic acid transfecting efficacy. However, DPI 
is still a promising technique for inhaled nucleic acid dependant on choosing the right excipient 
and vector as protective agents (Berghe et al. 2000, YT Chow and KW Lam 2015).     
 
 29 | P a g e  
 
Table 1– 3: Different types of techniques to produce dry powder  
Method Cost (commercial) Powder Yield Powder particle size and 
morphology 
 
Spray Drying 
 
Cost-effective (expensive in early stages), 
commercially available (Peltonen et al. 
2010)  
 
Relatively low recovery 
approximately 50%, It may increase 
depending on type of spray dryer (> 
70 %) formulation (Shoyele and 
Cawthorne 2006)  
Small, within range of 
inhalation and spherical 
shape (Liang et al. 2014)  
 
Spray Freeze drying 
High, and time consuming (Shoyele and 
Cawthorne 2006).  
High recovery (YT Chow and KW 
Lam 2015)  
Controllable size, relies on 
the excipients used and 
spherical in shape (Mohri et 
al. 2010, Amorij et al. 2008)    
 
Super Critical fluid drying  
Commercially, less available equipment  
(YT Chow and KW Lam 2015, Gradon 
and Sosnowski 2014)    
High, approximately 80 % 
(Okamoto et al. 2005) 
Controllable, depends on the 
excipients  (M Al-fagih et al. 
2011)  
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1.15 Thesis Aim and objectives  
Aim  
To design, formulate and characterise miRNA-containing NPs formulated as an inhalable dry 
powder microcarrier (Fig 1–7) for the treatment of Chronic Obstructive Pulmonary Disease 
(COPD).  
Objectives 
The aim of the thesis was achieved by the following objectives to; 
1. Formulate and develop polymeric NPs for miRNA delivery. 
a. Design and prepare optimized cationic PGA-co-PDL NPs using the cationic 
surfactant, DOTAP.  
b.  Investigate the influence of particle size and charge on lung cell uptake and 
toxicity.  
c. Adsorb miRNA onto the optimum NP formulation.  
d. Investigate the cellular uptake and the biological functionality of the miRNA-NPs.   
2. Formulate NCMPs for pulmonary delivery.  
a. Incorporate optimum NPs into NCMPs via spray drying with L-leucine and 
mannitol as microcarriers.  
b. Evaluate NCMPs containing miRNA-NPs for inhalation in terms of size, 
morphology, moisture content and aerosol performance.  
3. Evaluate in vitro, miRNA-NP NCMPs.  
a. Investigate miRNA functionality in terms of cellular uptake, interactions and gene 
knockdown. 
 
 
 31 | P a g e  
 
 
 
 
Figure 1 – 7. Illustration of pathway for formulation and pulmonary delivery of miRNA-
NPs incorporated into NCMPs.  
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2. Materials and General Methods 
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Materials  
Materials and Properties Supplier 
Poly (vinyl alcohol) PVA, Mw of 13- 23 kDa  
87-89% hydrolysed 
 
Clariant GmbH, Frankfurt am Main, 
Germany 
Divinyl adipate (DVA) Fluorochem, UK 
Novozyme 435 (a lipase lipase from Candida 
antartica immobilized on a microporous 
acrylic resin) 
 
Biocatalytics, USA 
Dichloromethane (DCM), 
Tetrahydrofuran (THF) 
Methanol (MeOH), 
Chloroform,  
Dimethyl sulfoxide (DMSO)  
Fischer chemicals (Fischer Scientific, 
UK) 
 
 
 
 
8 well chambered slides 
Opti-MEM® I Reduced Serum Medium 
Anti-actin beta rabbit monoclonal antibody  
Anti-Rb IgG (H+L) cross adsorbed secondary 
antibody HRP conjugates 
 
Thermo Fisher, scientific, UK 
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SuperSignal™ West Dura Extended Duration 
Substrate 
Bicinchoninic acid (BCA) protein assay kit  
Bovine serum albumin (BSA) 
L-glutamine  
6-well and 24-well tissue culture plates  
 25 and 75 cm2 tissue culture flasks 
Dioleoyltrimethylammoniumpropane 
(DOTAP) 
Avanti Polar lipids, Alabaster, AL, USA 
Glycerol  
ω-pentadecalactone (PDL) 
RPMI-1640 medium with L-glutamine and 
NaHCO3, 
Thiazolyl blue tetrazolium bromide (MTT),  
Phosphate Buffered Saline PBS tablets, pH 
7.4,  
 Nile red and 
 RNase-free diethyl pyrocarbonate (DEPC) 
water 
Paraformaldehyde (PFA)  
Sigma Aldrich (now Merck), UK. 
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Triton X-100  
10× TBE buffer (Tris-Borate electrophoresis 
buffer: 108 mg/mL Tris base,  
55 mg/mL Boric acid,  
9.3 mg/mL EDTA)  
9.4 Ethidium bromide (5 mg/mL) (EtBr) 
LB broth (Lennox) powder 
Anti-Mouse IgG (Fab specific) antibody  
Anti-Actin-Beta antibody, Rabbit monoclonal 
Penicillin-Streptomycin 
Trypsin-EDTA  
Sodium deoxycholate  
L-leucine 
D-Mannitol 
Complete™ ULTRA Tablets, Mini, 
EASYpack Protease Inhibitor Cocktail 
Sodium orthovanadate 
ß-mercaptoethanol  
Triton X-100 
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sodium dodecyl sulphate (SDS) 
Tris PH 8.0  
Unlabelled miR146a mimics  
Human adenocarcinomic alveolar basal 
epithelial cell line (A549).  
 Calu-3 cell lines  
Eagle's Minimum Essential Medium (EMEM)  
ATCC (Middlesex, UK) 
A synthetic miR-146a mimic with  6-
carboxyfluorescein ( FAM) -label on the sense 
5’ FAM-CCGGGCAAUUCAGUUUCUACA-
dTdT-3’ with the sequence: sense 5’ FAM-
CCGGGCAAUUCAGUUUCUACA-dTdT-3’, 
antisense 5’ dTdT-
GGCCCGUUAAGUCAAAGAUGU-3’  
Eurogenetec, UK 
Plasmid pMirTarget vector contains Firefly 
Luciferase and empty pMirTarget vector  
(Control) 
cDNA generations, PCR reagents and primers 
(IRAK, TRAF) 
3’-UTR reporter  
Origene  
Luciferase assay kit (cell lysis reagents)  
SOC media 
Promega’s, UK 
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Plasmid maxi prep purification kit 
Interleukin-1 receptor-associated kinase 
1 (IRAK1) RT² qPCR Primer  
 TNF receptor-associated factor 6 (TRAF6) 
RT² qPCR Primer  
RT² qPCR Primer Assay for Human GAPDH  
miScript SYBR® green PCR KIT 
miScript II RT Kit  
RNeasy Plus Mini Kit  
AllPrep DNA/RNA/miRNA Universal Kit  
 Qiagen, UK  
Lipofectamine 3000 and reagents  
 
Invitrogen (Life technology, UK).  
4′,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI) 
Invitrogen, Ltd.,UK.  
Precision Plus Protein™ Kaleidoscope™ 
Protein Standards  
Mini-PROTEAN® TGX Stain-Free™ Precast 
Gels 
Nitrocellulose membranes 
Bio Rad, UK  
Mouse monoclonal Anti-IRAK1 antibody  
Rabbit monoclonal Anti-TRAF6 antibody 
Abcam, UK 
10 X Tris/Glycine/SDS Geneflow Ltd , UK 
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 General Methods 
2.1 Polymer synthesis and characterisation 
Poly (glycerol adipate-co-ω-pentadecalactone), (PGA-co-PDL) was produced using an enzyme 
catalysed condensation and ring opening co-polymerisation reaction of equimolar quantities of 
the three monomers: divinyl adipate, glycerol, and ω-pentadecalactone (Fig. 2–1) as described 
by Thompson et al.  (Thompson et al. 2006). Briefly, a dry 250 ml two-necked round bottom 
flask, equipped with a central stirrer attached to a teflon paddle and open condenser, was 
charged with equal molar amounts (125 mmol) of divinyl adipate (DVA), pentadecalactone 
(PDL), glycerol and 25 ml of Tetrahydrofuran (THF). The flask was immersed in a water bath 
at 50 °C left to stir (210 rpm) for 20 minutes to equilibrate the temperature. Novozyme 435 
(1.25 g) was added, using the remaining THF (10 ml) to wash all the solid into the flask and 
the mixture stirred for 6 hours. Warm dichloromethane (DCM) (300 ml) was added to the flask 
followed by Buchner filtration to remove the solid enzyme. The solvent was then removed by 
rotary evaporation (60 °C) until around 20 ml of DCM remained. Methanol (100 ml) was added 
to precipitate the polymer and leave unreacted monomers and oligomers in solution which were 
Foetal Bovine Serum (FBS) 
 
Biosera, UK. 
96-well tissue culture plates, black,  flat 
bottom 
 
Griener Bio-one, UK 
213 - pIL8/d2EGFP and 269 - pDSRED mono 
promoters 
A kind gift from Dr. Endre Kiss-Toth, 
Sheffield, UK.   
Interleukin 8 (IL8) promoter and tumor 
necrosis factor-a (TNFa)  
Peprotech, UK.  
 39 | P a g e  
 
filtered using Buchner filtration. The precipitate was broken up and left to dry under vacuum 
for 24 h before grinding into a powder and storing in a desiccator at room temperature.  
For further explanation to Fig. 2–1, the PGA-co-PDL was prepared from co-polymerisation of 
three monomers; PDL, DVA and glycerol with aid of a hydrolytic enzyme (Novozyme 435) to 
produce PGA-co-PDL as a linear polyester. The enzyme chosen for this polymerisation 
reaction has a regio-selectivity for primary hydroxyl (OH) groups (Kline et al. 1998).  
 
 
Figure 2– 1. The reaction scheme for the enzymatic synthesis of PGA-co-PDL (Thompson 
et al. 2006).   
 
The PGA-co-PDL was analysed by Nuclear Magnetic Resonance (1H NMR), using a Bruker 
Avence 300 MHz spectrometer, inverse probe with B-ACS 60 and auto sampler with gradient 
shimming. Gel permeation chromatography (GPC) using a Viscotek TDA Model 300 
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(OmniSEC3 software), the system was fitted with two PLgel 5 µm MIXED-D 300x7.5 mm 
columns (Varian, Polymer Laboratories, UK), stored in the detector oven at 40 °C, and a flow 
rate of 1  ml/min using chloroform as a solvent. The system was pre-calibrated with polystyrene 
standards.  
2.2 Nanoparticle preparation and miR-146a adsorption 
PGA-co-PDL nanoparticles (NPs) were prepared using an oil in water (o/w) single emulsion   
method as previously described (Kunda et al. 2014a). Briefly, 200 mg PGA-co-PDL and 
optimum 15 % dioleoyltrimethylammoniumpropan (DOTAP) were dissolved in 2 ml DCM, 
and upon adding 5 ml 10 % w/v poly (vinyl alcohol) (PVA) (1st aqueous solution ) drop wise 
on ice using probe sonicated (20 μm amplitude) for about 2 minutes to obtain an emulsion. 
This was immediately added drop wise to 20 ml of a 2nd aqueous solution (0.75 % w/v PVA) 
under magnetic stirring at a speed of 500 RPM and stirred at room temperature for 3 h to 
facilitate the evaporation of DCM. The NPs suspensions were collected by ultracentrifugation 
at 35,000 x g, for 40 min at 4 °C using (Beckman L-80 Ultracentrifuge, UK) and washing twice 
with distilled water (4 ml) to remove excess surfactants. 
For adsorption, miR-146a was adsorbed onto the NPs suspension obtained after centrifugation 
following removal of excess surfactant. 6-carboxyfluorescein (FAM) labelled miR-146a, and 
unlabelled miR146a-NPs (for IL-8 Promoter Reporter assay),  (40 µg) was added to a 1 ml 
solution of RNase free water containing 10 mg of NPs (to obtain a final NP:miRNA weight 
ratio of 250:1) and mixed using a HulaMixerTM Sample Mixer (Life technologiesTM, UK) at 
20 rpm and 25 °C for 2 h. RNase free water was then added to a total volume of 4 ml prior to 
separation of non-adsorbed miR-146a by a single ultracentrifugation at 35,000 x g, for 40 min 
at 4 °C using (Beckman L-80 Ultracentrifuge, UK) (Fig 2–2). The concentration of free miR-
146a in the supernatant was analysed by UV prior further use.  
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Figure 2– 2. Adsorption of negatively charged miRNA onto positively charged NPs. 
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2.3 Nanoparticle characterisation 
 2.3.1 Particle size and zeta potential  
The mean particle size and polydispersity index (PDI) were analysed by dynamic laser 
scattering, and the surface charge of the particles was determined by measuring the zeta-
potential (Zetasizer Nano ZS, Malvern Instruments Ltd, UK) in triplicate and for three different 
NPs batches. NPs (10 mgs) were diluted with 4 ml distilled water and 1 ml of the diluted sample 
was loaded into a measuring cuvette and the measurements were recorded at 25 °C.  
2.3.2 miRNA adsorption  
To determine the amount of miRNA adsorbed to the NPs, the concentration of adsorbed miR-
146a determined indirectly from the difference in miR-146a concentration before and after 
loading by UV absorbance at 260 nm using a NanoDrop 2000C (Thermo Fisher Scientific, and 
USA). In addition, the concentration of 6-carboxyfluorescein (FAM) labelled miR-146a was 
determined by fluorescence using a plate reader (CLARIOstar®, BMG) at λEX: 495 nm; λEm; 
520 nm. In both cases, a calibration curve was generated using known concentrations of 
miR146a. Excitation wavelength 496 nm green laser.   
2.4 Real time quantitative polymerase chain reaction RT-qPCR  
 2.4.1 RNA extraction  
miR-146a-NPs/NCMPs in serum free medium were incubated with A549 cells for 1 h. The 
miR146a-NPs/NCMPs mixture was then replaced with complete medium and the cells 
incubated for 24 h. The total RNA was extracted from the cells using the miRNA mini kit II 
according to the manufacturer’s instructions (Qiagen, Manchester, UK). Briefly, cells were 
trypsinised by trypsin-EDTA, washed with PBS twice and collected by adding PBS and serum 
free medium and collecting the cells by centrifugation at 300 x g for 5 minutes. The cells were 
disrupted by adding buffer RLT plus containing β-mercaptoethanol (100:1). The homogenised 
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lysate was vortexed for 30 s and transferred to an AllPrep DNA spin column and centrifuged 
for 30 s at 8000 x g. The aqueous flow-through was mixed by pipetting with 350 µl of 70 % 
ethanol. a 700 µl of sample was transferred to an RNeasy spin column and centrifuged for 15 
s at 8000 x g. The aqueous flow-through was discarded and 700 µl buffer RW1 was added to 
RNeasy spin column and centrifuged for 15 s at 8000 x g. The flow-through was discarded and 
500 µl buffer RPE added to the RNeasy spin column, and centrifuged for 15 s at 8000 x g. The 
RNeasy spin column was washed again with 500 µl buffer RPE and centrifuged for 2 min at 
8000 x g then re-centrifuged again for 1 min at 8000 x g to dry and eliminate any possible 
carryover of buffer RPE. The RNeasy spin column was placed in a new microcentrifuge tube 
and 40 µl RNase-free water added followed by centrifugation for 1 min at 8000 x g to elute the 
RNA. RNase-free water (40 µl) was added and then centrifuged for 1 min at 8000 x g. The 
RNA extract was tested for purity and concentration at 260 nm using a NanoDrop 
spectrophotometry (Thermo scientific). 
 2.4.2 cDNA generation  
Qiagen miRScript reagents were used to convert mature mRNA to cDNA (Fig. 2–3).  miScript 
HiFlex buffer was used with 1 µg RNA and incubated with a master mix of reverse 
transcriptase, dNTPs and both oligo-dT and random primers (Table 2–1). The reaction was 
heated to 37°C for 60 min followed by 5 min incubation at 95°C to inactivate the reverse 
transcriptase. cDNA was stored at -20°C for further experimental work.  
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Figure 2– 3. Conversion RNA into cDNA in miScript HiFlex buffer. In a reverse 
transcription reaction with miScript HiFlex Buffer. mRNAs are converted into cDNA by 
reverse transcriptase using both oligo-dT and random priming. Detection of mRNA can 
be performed using real-time PCR (Qiagen miScript PCR handbook).    
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      Table 2– 1.  Reverse transcription reaction components 
Component Volume 
5x miScript HiFlex Buffer 4 μl 
 10x miScript Nucleics Mix 2 μl 
miScript Reverse Transcriptase Mix 2 μl 
 
 2.4.3 Polymerase chain reaction  
cDNA reaction was diluted with 200 ul of RNAse-free water. Levels of IRAK1 and TRAF6 
transcripts were assessed using RT2 qPCR Primer Assays in 20 µl reactions composed of 10 µl 
SYBR Green PCR master mix, 2 µl primers, 2 µl diluted cDNA and water to 20 µl. The 
reactions were amplified for three-step method (Table 2–2). The expression of IRAK1 and 
TRAF6 was normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression.  
Data were analysed using the 2− ∆∆Ct  method  (Livak and Schmittgen 2001).  
 Table 2– 2. Cycling conditions for RT-PCR 
Step Time Temperature 
PCR initial activation step 15 min 95 °C 
Denaturation 15 s 94°C 
Annealing 30 s 55 °C 
Extension 30 s 70 °C 
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2.5 Effect of miR-146a-NPs/NCMPs on protein expression  
2.5.1 Western Blot  
A549 cells were seeded at a density of 3.8× 105 cells per well in a 6 well plate. After 24 h 
growth, the cells were incubated in serum free medium with 1 ml of pre-mixed freshly prepared 
miR146a-NPs and miR146a-NP-NCMPs at a range of concentration (0 – 0.625 mg/ml), (Table 
2–3) for 1 h. The miR-146a-NPs/NCMPs mixture was then replaced with complete medium 
and the cells incubated for 24 h and 48 h respectively. The medium was discarded and the 
plates were rinsed twice with PBS, followed by adding lysis buffer (Radio Immuno 
Precipitation Assay, RIPA) on ice. RIPA buffer contains 150 mM sodium chloride, 1 % Triton 
X-100, 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulphate (SDS), 50 mM Tris PH 
8.0, sodium orthovandate and protease inhibitor tablet (Roche), then left to agitate for 15 
minutes at room temperature. A plastic cell scraper was used to scrape and collect the 
homogenate which was then centrifuged at 10,000 x g for 1 min at 4˚C and the supernatant 
collected.  The protein content of the supernatant was determined using a bicinchoninic acid 
assay, BCA (Sigma, UK). Samples (4 parts) were diluted with an equal volume of 1 part 
Laemmli buffer (0.5 M Tris-HCL PH 6.8, glycerol, SDS, 0.25 % bromophenol blue, β-
mercaptoethanol) and boiled for 5 min at 95 ˚C. For each lane protein standards and extracts 
(20 µg) were resolved on 12 % precast gel (Bio-Rad, UK) and transferred to nitrocellulose 
membranes (Bio-Rad, UK) in Tris-glycine buffer with 20 % methanol. After transfer, 
membranes were blocked for 1 h at room temperature in 5 % fat free milk in TBST (TBS and 
Tween-20). The membranes were then washed for 3 x 5 min in TBST before probing overnight 
at 4˚C with antibodies anti-IRAK1 (1:1000, Abcam), anti-TRAF6 (1:1000, Abcam), β-Actin 
(1:1000, ThermoFischer). Membranes were washed for a further 3 x 5 min in TBST then 
incubated with horseradish Peroxidase conjugated secondary antibodies (1:5000, sigma) for 1 
h at room temperature. After a further 3 x 5 min washes in TBS, membranes were exposed in 
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a chemiluminescence Pierce ECL reagents (Thermo Fisher,UK) according to manufacturer’s 
protocol. Densitometry was performed using ImgaeJ software, and protein of interest values 
were used to normalize against β-Actin values. 
 
 Table 2– 3. Shows miR-146a-NPs/NCMPs concentrations used 
Lane NPs/NCMPs 
  concentration (mg) 
miR-146a  
concentration (µg) 
1 Control Control 
2 0.078 0.25 
3 0.156 0.50 
4 0.321 1.00 
5 0.625 2.01 
 
2.6 Statistical analysis  
All statistical analysis was performed using Minitab® 16 Statistical Software. One-way 
analysis of variance (ANOVA) with the Tukey’s comparison was employed for comparing the 
formulations with each other. Statistically significant differences were assumed when p<0.05.  
Statistical analyses were performed in GraphPad Prism 5 (GraphPad Software, Inc., San 
Diego,CA). All values are expressed as their mean ± standard deviation (SD). 
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3. Polymeric Nanoparticles for the 
Delivery of miRNA to Treat Chronic 
Obstructive Pulmonary Disease (COPD) 
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3.1 Introduction  
Small nucleic acids such as miRNA have recently gained significant attention as a new class 
of therapeutics for various genetic diseases. Modulation of miRNA expression and function 
represents a promising strategy for therapeutic intervention in disorders such as inflammatory 
lung disease, particularly COPD. There is a relationship between miRNA (miR-146a) and 
inflammatory response in COPD pathogenesis (Sato et al. 2010).  
Pulmonary drug delivery is a non-invasive route that can be utilised to deliver molecules to 
lung cells. However, one of the main issues with delivering miRNAs to the inflammatory lung 
tissue is that upon delivery of the naked, negatively charged miRNAs to the site of action, the 
molecules cannot cross the anionic cell membranes, and are degraded by physiological 
enzymes  (Guzman‐Villanueva et al. 2012). Therefore, the challenge is to design a delivery 
system capable of protecting and transporting the miRNA through these biological barriers to 
reach the site of action (Yin et al. 2014).  
Viral vectors have historically been used as carriers for small nucleic acid delivery but have 
the  disadvantagee of causing an immunogenic inflammatory  repsonse (Wang et al. 2012b). 
Consequently, more attention has been given to non-viral delivery vectors such as 
biodegradable polymeric NPs. These NPs have previosuly been considered for delivery small 
mucleic acids (Labiris and Dolovich 2003b).  
Polymeric NPs can offer properties such as targeted delivery, sustained release, biodegradation, 
and low toxicity (Panyam and Labhasetwar 2003).  NPs have an electrostatic charge on their 
surface that affects the interaction between the particles and cell membrane surfaces as the 
neutralization of the charge can lead to increased bio-distribution. Furthermore, the surface 
electrostatic charge can enhance particle uptake into cells when positively charged particles 
bind to the negatively charged cell membrane and undergo endocytosis (Somasundaran et al. 
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2004). Additionally, the electrical potential and surrounding surface charge prevent 
aggregation of NPs (Somasundaran et al. 2004) and can interact with negatively charged small 
neuclic acid  leading to particle uptake and increasing bio-distribution (Hwang and Davis 2001, 
Hamdy et al. 2011). Compared to encapsulation of nucleic acids within NPs, which includes 
exposure to solvent, sonication and mechanical stress during processing, the adsorption of 
small nucleic acid s onto the NP surface can provide enhanced stability and activity, (Cun et 
al. 2010). The difficulty in loading of miRNA into NPs can be attributed to the hydrophobic 
nature of NPs and the absence of electrostatic interaction between miRNA and NPs.  
The cationic lipid  dioleoyltrimethylammoniumpropane (DOTAP) has previously been used as 
a transfection agent, forming lipolexes with negatively charged small-interfering RNA and 
increasing their cellular interaction (Li et al. 2014, Ozpolat et al. 2010).  It has also be used to 
preapre cationic NPs  that showed biocompitability with small nuclic acid and genes (Kumar 
et al. 2012, Díez et al. 2009b). Therefore,  cationic NPs  may have the potential to serve as 
small nucleic acid carriers.   
PGA-co-PDL NPs has previously  been investigated as carriers for both small molecules and 
macromolecules by encapsulation of the molecules within the particle (Kallinteri et al. 2005, 
Gaskell et al. 2008, Tawfeek et al. 2013) or adsorption to the surface (Kunda et al. 2014b, 
Tawfeek et al. 2011).  
3.2 Aim  
The aim of this study was to adsorb  miRNA on to the surface of cationic PGA-co-PDL NPs, 
and evaluate  toxicity,  and cell uptake.  
To obtain the aim of the study, the following objectives were considered;  
 51 | P a g e  
 
1. Design and prepare optimized cationic PGA-co-PDL NPs using cationic surfactants 
(DOTAP).  
2. The influence of particle size and charge on A549 and Calu-3 lung cells, toxicity and 
cell uptake. 
3. Adsorption of miR-146a on to the surface of cationic PGA-co-PDL NPs.  
3.3 Methods 
3.3.1 Polymer synthesis and characterisation  
The PGA-co-PDL was synthesised and characterised as described in section 2.1.  
3.3.2 Nanoparticle preparation and miRNA adsorption  
PGA-co-PDL NPs were prepared using an oil in water (o/w) single emulsion method as 
described in our previously published method, incorporating 0.4 mg Nile red dye in the inner 
organic phase for visualization experiments  (Kunda et al. 2014b) and different concentrations 
of DOTAP to prepare cationic NPs (DOTAP is % w/w of polymer) (Table 3–1).  
Different quantities of miR-146a (10, 20, 30 and 40 µg) were added to a 1 ml solution of RNase 
free water containing 10 mg of NPs (to obtain a final NP:miRNA weight ratio of 250:1 and 
mixed using a HulaMixerTM Sample Mixer (Life TechnologiesTM, UK) at 20 rpm and 25°C 
at different time points (0.5, 1, 2, 4 and 24 h). After adsorption, RNase-free water was added 
to a total volume of 4 ml prior to separation of free miRNA from the adsorbed miRNA by 
ultracentrifugation at 35,000 x g, for 40 mins at 4°C using (Beckman L-80 Ultracentrifuge, 
UK).  
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Table 3– 1. Different DOTAP to PGA-co-PDL concentration. 
DOTAP Conc. 
(%) 
PGA-co-PDL (mg/ml) DOTAP (mg/ml) 
0 200 0 
5 190 10 
10 180 20 
15 170 30 
20 160 40 
25 150 50 
 
3.3.3 Particle size, zeta potential and miRNA adsorption characterisation 
The particle size, zeta potential and miRNA adsorption were characterised as detailed in 
section 2.3.  
3.3.4 In vitro release 
The miR146a-adsorbed PGA-co-PDL NPs (10 mg) were suspended in a tube containing 4 ml 
PBS (pH 7.4) and incubated at 37°C, rotating at 20 rpm on a HulaMixerTM Sample Mixer. At 
various time points, the samples were centrifuged at 35000 x g for 40 min and 1 ml of 
supernatant was collected for quantification, replaced with fresh aliquot (1 ml) of PBS and 
incubation resumed. The supernatant was analysed as described in 2.3.2. The amount of 
released miR146a was calculated as percentage of cumulative released miR146a to the total 
amount of adsorbed miR146a (Eq.1).  
% Cumulative miR146a released = 
Cumulative miR146a released
miR146a loaded
 × 100    (Eq.1) 
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3.3.5 Cell Viability study 
3.3.5.1 Cell culture and toxicity studies 
Adenocarcinomic human alveolar basal epithelial cell lines (A549) were maintained in RPMI-
1640 supplemented with 100 U/ml penicillin, 100 µg /ml streptomycin, 2 mM L-glutamine and 
10% (v/v) fetal bovine serum (FBS). Epithelial cell lines (Calu-3)  were grown in Eagle's 
Minimum Essential Medium (EMEM) containing balanced salt solution, non-essential amino 
acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 1500 mg/L sodium bicarbonate and 
supplemented with 100 U/ml penicillin, 100 µg /ml streptomycin and 10% (v/v) fetal calf 
serum (not heat treated). The cell culture medium was changed every 2 days and the cells were 
checked under a microscope to determine the confluency and to confirm the absence of 
contamination. Both cells were grown in an atmosphere of 5 % CO2 and 95 % O2 at 37°C. The 
cells were trypsinised with trypsin-EDTA once 80-90 % confluency was reached, then, either 
passaged to a new flask or plated in 96 well plates for toxicity and transfection experiments. 
3.3.5.2 MTT toxicity assay 
 
The cytotoxicity of the NPs was determined in vitro with the MTT (3[4, 5-dimethylthiazol- 
2-yl]-2, 5-diphenyl tetrazolium bromide) assay, using A549 and calu-3 cells.  MTT is a 
tetrazolium dye that upon reduction by mitochondrial enzymes changes colour from yellow to 
blue. The colour intensity is directly related to the viability of the cells. The cells were seeded 
in a 96-well plate in growth medium at density of 1.2× 105 cells per well. After 24 h growth 
(80 % confluence), the cells were incubated with 100 µl of pre-mixed freshly prepared  NPs at 
a range of concentration (0 - 2.5 mg/ml) using 10 % dimethyl sulfoxide (DMSO) as a positive 
control. The medium was then removed after 18 h and 40 µl of the MTT solution (5 mg/ml in 
PBS) added to each well and incubated for 2 h. The MTT medium was removed and the 
formazan precipitate dissolved using 100 µl DMSO. The absorbance of each well was 
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measured at 570 nm and the cell viability percentage calculated as the absorbance ratio between 
treated and blank cells (control). The assay was performed on three occasions with three 
replicates for each concentration.  
 
3.3.6 Cell Imaging 
3.3.6.1 Confocal and Fluorescence Microscopy 
A549 cells were seeded on a 8-well chambered slide (Fisher Scientific, UK) at a seeding density 
of 5× 105 cells per well and incubated overnight. The cell culture media was removed and 
replaced with 500 µl of FAM-labelled miR-146a-NPs and Nile Red NPs in serum free medium, 
RPMI-1640 for 1 h (37°C, 5 % CO2). After this time, the media was removed from the cells to 
allow confocal imaging. In brief (Table 3–2), cells were washed with 3 x PBS for 5 min each 
and fixed using 4% paraformaldehyde (PFA) or ice-cold (-20°C) methanol was used for 15 
min. Methanol or PFA was then removed and 0.1% Triton-X 100 was added for 10-15 min at 
room temperature for permeabilization. In order to stain the nucleus, 1 µg/ml DAPI was added 
for 5 min, then removed and washed with PBS and mounting medium was added on coverslip. 
Confocal images were acquired using a Zeiss LSM 710 confocal microscope using an oil 
immersion objective 40x and 60x. Images of FAM labelled miR146a-NPs were captured using 
an excitation wavelength 496 nm (green laser), Nile Red NPs were captured at 543 nm (green, 
red and blue channels). Additionally, the slides were observed under an Olympus BX51 
Fluorescent microscope. Images were collected in a 8-bit format. These procedures were 
performed in the dark.  
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Table 3– 2. Workflow for staining A549 cells for confocal microscope 
Step Treatment Composition 
1. Washing  3 x rinse, Room Temp 
(RT) 
PBS 
2. Fixation  15 min, RT 4% PFA or -20°C 
methanol 
3. Washing  1 x Rinse, RT PBS 
4. Permeabilization 15 min, RT 0.1% Triton-X 100 
5. Washing  1 x Rinse, RT PBS 
6. Nucleus stain  5 min, RT 1 µg/ml DAPI 
7. Washing  1 x Rinse, RT PBS 
 
 
 
3.3.7 Statistical analysis  
All statistical analysis were performed using Minitab® 16 Statistical Software. One-way 
analysis of variance (ANOVA) with the Tukey’s comparison was employed for comparing the 
formulations with each other. Statistically significant differences were assumed when p<0.05.  
Statistical analyses were performed in GraphPad Prism 5 (GraphPad Software, Inc., San 
Diego,CA). All values are expressed as their mean ± standard deviation (SD). 
3.4 Results  
3.4.1 Polymer synthesis and characterisation  
The PGA-co-PDL (a ratio of monomers, 1:1:1) obtained was a white powder with a molecular 
weight of 16 kDa, as determined by GPC. The structure of PGA-co-PDL was determined by 
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1H-NMR as described previously (Thompson et al. 2006) (δH CDCl3, 300 MHz): 1.34 (s, 22H, 
H-g), 1.65 (m, 8H), 2.32 (m, 6H), 4.05 (q)-4.18 (m) (6H), 5.2 (s, H). The Infra-red spectrum 
showed a typical broad shallow –OH band at 3447.0 cm1, –CH2 groups of DVA, PDL, at 
2915.7 cm1, –CH group of glycerol at 2848.4 cm1, the carbonyl group of DVA and lactone 
monomers at 1730.7 cm1, C–O group of lactone, glycerol at 1417.0 and 1164.8 cm1.  
3.4.2 Particle size and Zeta Potential  
NPs with and without DOTAP were prepared using a single emulsion solvent evaporation 
method adding the DOTAP, where relevant, in the organic phase at various DOTAP to PGA-
co-PDL concentration. Varying the concentration of DOTAP incorporated into the PGA-co-
PDL NPs resulted in a change in particle size from 266.10±20.80 nm at 0 % (w/w)  DOTAP to 
197.90±1.70 nm at 20 % (w/w) DOTAP and, a change in surface charge from -18.9±0.9 mV 
to +16.7±0.1 mV as the DOTAP concentration increased (Fig. 3–1). The particle size and zeta 
potential of the DOTAP-NPs varied-only slightly above a concentration of 15 % (w/w) 
DOTAP. Therefore 15 % (w/w) DOTAP was subsequently used in all NPs formulations.  
 
At this DOTAP concentration miR-146a loaded cationic NPs (miR-146a-NP), were the same 
size as unloaded NPs (244.8±4.4 nm and 242.4±0.3 nm, respectively). The charge after 
adsorption of miR-146a onto the NP surface ranged between +5.9 mV to +11.1 mV depending 
on the amount of miR-146a adsorbed, compared to +14.8±0.2 mV for unloaded NPs, showing 
the miR-146a loaded NPs retained a positive charged. The observed reduction in Zeta potential 
confirmed the miR-146a was adsorbed.  
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Figure 3 – 1.   (A) The effect of the concentration of DOTAP on particle size of PGA-co-
PDL NPs and  (B) The effect of the concentration of DOTAP on the particle surface 
charge of PGA-co-PDL NPs. Data represented in A and B are Mean ± SD (n=3). 
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3.4.3 miR-146a adsorption 
The 15 % (w/w) DOTAP NPs were used to study miR-146a adsorption by first using a fixed 
miR-146a concentration (40 µg/ml) at different time points 0.5, 1, 2, 4 and 24 h (Fig. 3–2A). 
After 0.5 h, 12.05 ± 1.3 µg of miR-146a (40 µg/ml) was adsorbed onto 10 mg of NPs. The 
maximum miR-146a adsorption was 36.25±0.35 µg miR-146a per 10 mg NPs after 24 h. 
Beyond 2 h there was no significant difference in miR-146a adsorption with a maximum of 
32.25±2.0 µg miR-146a per 10 mg NPs (p <0.05, ANOVA/ Tukey’s comparison). 
Furthermore, adsorption of miR-146a at different concentrations with a fixed time of 2 h was 
investigated. As shown in (Fig. 3–2B) over 50% of the miR-146a was adsorbed at 
concentrations of 20, 30 and 40 µg miR-146a. The positively charged NPs attract the negatively 
charged miR-146a by electrostatic interaction. Therefore, the results indicate that 15 % (w/w) 
DOTAP NPs can be effectively adsorbed with miR-146a.  
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Figure 3 – 2. (A) Adsorption of miRNA (40 µg/ml) at different time points up to 24 h onto 
15 % DOTAP NPs, * is p <0.05, ANOVA/ Tukey’s comparison. (B) miRNA adsorption 
onto 15 % DOTAP NPs at various miRNA concentrations over 2 h, µg miRNA per 10 mg 
NPs.  Data is presented as Mean ± SD (n=2).  
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Confirmation that the miRNA was associated with the NPs was achieved using Fluorescence 
microscopy. Fig. 3–3 indicates the fluorescently labeled NPs (Nile Red dye) with labelled 
FAM-miR-146a (green) were bound and adsorbed.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – 3.  Image (A) shows red colour collection of NPs (Nile Red dye), (B) the labelled 
FAM-miRNA (Green) and (C) the merged image of both A and B (scale bar represents 
50 µm). 
 
 
 
3.4.4 In vitro cytotoxicity  
To assess the toxicity profile of the PGA-co-PDL NPs with DOTAP, different DOTAP 
concentrations (0 – 25 %) were investigated using the MTT assay. Fig. 3–4A illustrates that 
decrease in cell viability and an increase in concentration and the 15 % DOTAP particles were 
A B C 
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then further investigated for toxicity based on size (section 3.4.2) and compared with unloaded 
NPs. Blank cells (control) had 100 % cell viability, whereas cell viability at 1.25 mg/ml were 
around 90 % (unloaded NPs) that decreased to 65 % (15 % DOTAP NPs) (Fig. 3–4B), 
indicating the NPs appear to cause cell death with an increase in concentration after 18 h 
exposure (Fischer et al. 2003, Bose et al. 2015). 15 % DOTAP NPs at 1.25 mg/ml concentration 
showed calu-3 cells remained viable following 18 h exposure (Fig. 3–4C). 
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Figure 3– 4.  (A) Cytotoxic effect of cationic PGA-co-PDL NPs (0 % - 25 % DOTAP) after 
18 h incubation. (B) Cytotoxic effect of unloaded NPs (0 % DOTAP) and 15 % DOTAP 
NPs on A549 cells after 18 h incubation. (C) Cell viability of A549 and calu-3 cells with 
15% DOTAP NPs after 18 h incubation. DMSO was used as positive control, the cell 
viability was measured using MTT assay. The experiments were repeated three times and 
data represented as mean ± SD (n=3), (*p<0.05, ANOVA/Tukey’s).   
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3.4.5 In vitro release 
The in vitro release profile of the miR-146a -loaded NPs (40 µg/ml) showed that the release 
could be divided into two stages (Fig. 3–5). The miR-146a was initially rapidly released in the 
first 4 h with a 51±1.5 % cumulative release. Followed by a second stage during which the 
miR-146a was constantly released from 4 h up to 24 h, to a cumulative release of 77±1.5 %.  
 
 
 
 
Figure 3 – 5.  miRNA in vitro release from 15 % DOTAP NPs in phosphate buffer saline 
at pH 7.4. Data presented as Mean ± SD (n=3). 
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3.4.6 Cellular uptake   
To visualise the cellular uptake of the NPs for delivery to A549 cells, NPs encapsulating Nile 
red dye were prepared and added to A549 cells. The NPs were observed to be distributed in the 
perinuclear region, in large populations of cells and single cells, indicating that the NPs were 
taken up by the cells (Fig. 3–6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – 6. Fluorescence (A–C) and confocal (D–F) images of Nile Red NPs in A549 
cells. (A&D) Nucleus is stained with DAPI, (B & E) NPs stained with Nile Red dye and 
(C&F) merged image after 1 h of incubation. The scale bars (A–C) represent 20 µm and 
(D–F) represent 10 µm. 
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Furthermore, to visualize the intracellular uptake of FAM-labelled miR-146a-NPs for delivery 
to A549 cells, FAM-labelled miR-146a-NPs were prepared and exposed to A549 cells. Large 
populations of cells were stained with DAPI, and particles were distributed differentially across 
a population of cells with a clear variation (Fig. 3–7 A, B and C). The same results were 
obtained with a single cell where the particles can be observed around perinuclear distribution 
(Fig. 3–7 D, E and F).  
 
 
 
 
 
 
 
 
 
 
Figure 3– 7. Fluorescence (A–C) and confocal (D–F) images in A549 Cells. (A&D) Nucleus 
is stained with DAPI, (B&E) FAM-labelled miR-146a-NPs and (C&F) merged image 
after 1 h of incubation. The scale bars (A–C) represent 20 µm and (D–F) represent 10 µm. 
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3.5 Discussion 
3.5.1 Optimization of cationic NPs 
In this study, the effect of cationic lipid DOTAP on particle size and surface charge of NPs was 
investigated.  The physicochemical properties of cationic NPs were consistent with those 
previously reported in the literature (Jensen et al. 2012). DOTAP has previously been used in 
other studies as a cationic material to modify polymeric NP properties such as particle size, 
charge and improve gene transfection (Kumar et al. 2004). DOTAP is thought to  limit the 
enlargement of polymeric NPs due to its surfactant and condensation characteristics (Jensen et 
al. 2012). Another reason for the change in particle size is that the cationic material has the 
ability to decrease interfacial tension between the particle surface and the aqueous phase during 
formation  (Song et al. 2006a).  This is similar to the effect of PVA on particle size during 
preparation of NPs (Murakami et al. 1997), where the particle size decreased due to an adequate 
amount of surfactant covering the surface of PGA-co-PDL NPs (Kunda et al. 2014b).  
 
The electrostatic interaction between the DOTAP cationic moiety, quaternary amine and the 
negatively charged PGA-co-PDL neutralises the PGA-co-PDL and the remaining amine groups 
cause the positive charge (Hagigit et al. 2008, Campbell et al. 2001, Mura et al. 2011). This 
positive charge on the particle surface can potentially interact with biomolecules. PGA-co-PDL 
NPs have the ability to combine with other cationic compounds leading to a change in particle 
size and charge. Kunda et al. used DMAB as a cationic surfactant to prepare positively charged 
PGA-co-PDL NPs and observed similar results to ours  in which PGA-co-PDL NPs ability to 
become cationic  (Kunda et al. 2014b).  
 67 | P a g e  
 
The data presented in this study indicate that PGA-co-PDL mixed with DOTAP formed 
cationic NPs using 10 % to 25 % (w/w) DOTAP. It was noted that increasing the concentration 
of DOTAP decreased particle size and caused the zeta potential to become more positive (Fig 
3–1).  
The particle size and zeta potential of the DOTAP-NPs showed only slight differences above 
a concentration of 15 % (w/w) DOTAP. However, there was little change in particle properties 
from 15 % to 20 % (w/w) so given the increased cost and toxicity of using higher DOTAP 
concentrations, 15 % (w/w)  DOTAP was chosen for all future work and was selected for the 
subsequent miRNA adsorption studies. The particle size of 5 % and 10 % (w/w)  DOTAP was 
significantly higher compared with other concentrations (15 % - 25 % (w/w)  DOTAP), 
suggesting that this larger particle size was due to particle aggregation and surface tension (Cui 
and Mumper 2001, Bose et al. 2015). This particle aggregation was due to the electrostatic 
interaction of negatively charged PGA-co-PDL and positively charged DOTAP, which caused 
electrostatic repulsion making the low DOTAP concentrations 5 % and 10 % (w/w) produce 
larger particle sizes. It appears that the particles with higher DOTAP concentrations (15 % - 25 
% (w/w) stabilized PGA-co-PDL more efficiently than at lower concentrations 5 % and 10 % 
(w/w).  Thus, the particle size was proportionally related to the DOTAP concentration (Bose 
et al. 2015).  
 
This data agrees with previous research indicating that the use of DOTAP during particle 
preparation affects the particle size. Jensen et al. used DOTAP with PLGA for siRNA delivery, 
and reported that particle size was decreased from 260.8±14.1 nm to 207.7±0.1 nm after use of 
various DOTAP concentrations, included during preparation (Jensen et al. 2012).  
Also, DOTAP reduced the size of spontaneously-forming PC-containing liposomes, allowing  
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the liposomes to become positively charged and enhance cellular interaction (Campbell et al. 
2001). The particle surface charge is another important factor for miRNA adsorption and 
cellular uptake. The effect of DOTAP concentration on NPs surface charge was investigated 
(Fig 3–1). As DOTAP concentration increased, the surface charge increased changing to a 
positive charge compared with negatively charged NP formulated without DOTAP -18.9±0.90 
mV. 
This electrostatic surface charge affects the adsorption of miR-146a, and addition of negatively 
charged miR-146a lead to a slight charge reduction in cationic NPs. This could be attributed to 
the decreased surface area of cationic NPs and  ionic interactions (Bose et al. 2015, Kumar et 
al. 2012). The charge of cationic NPs remained positive after miR-146a adsorption, and the 
amount of miR-146a adsorbed on cationic NPs (Fig. 3–2A) over different time points indicated 
that the surface of cationic NPs was saturated with miR-146a after 2 h, suggesting the 
maximum adsorption time, which results in good affinity to anionic cell surface.  However, 
when the amounts of miR-146a are added to cationic NPs indicated (Fig. 3–2B) there was an  
equilibrium condition which did not reach the point of saturation and which suggests a positive 
charge of cationic NPs after miR-146a adsorption.  
3.5.2 Toxicity studies and in vitro release 
The MTT assay was used to determine the cytotoxicity of PGA-co-PDL NPs with 15 % (w/w) 
DOTAP concentration on A549 and calu-3 cells. It was previously reported that PGA-co-PDL 
NPs had a little effect on A549 cell viability (>75 % at 1.25 mg/ml) on lung bronchial epithelial 
cells with cell viability studies (Alfagih et al. 2015), whereas our unloaded NPs had 90 % at 
1.25 mg/ml.  
The concentration of optimum 15 % DOTAP NPs caused changes in cell viability, those 
without DOTAP had 96 % viability at 0.312 mg/ml, which decreased to 77 % with 15 % 
DOTAP NPs at 0.312 mg/ml. The toxicity measured here is of a high particle concentration in 
 69 | P a g e  
 
a relatively small surface area in 96 well plate, whereas in the lungs, the NPs will be more 
dispersed, thus the high level of particle toxicity shown here is unlikely to be seen in lungs 
(Kunda et al. 2015a). These results support previous literature studies that have used A549 and 
calu-3 respiratory cell lines to evaluate the in vitro toxicological effect  of particulate drug 
delivery systems (Foster et al. 2001, Seagrave and Nikula 2001). Grenha et al. used A549 and 
calu-3 cells to study particle toxicity, where chitosan NPs entrapped in mannitol reduced cell 
viability ( ∼ 65 % ) and were in vitro compatible with A549 and calu-3 cells (Grenha et al. 
2007).  
The cationic lipid DOTAP also influences the cytotoxicity, and Bose et al. found that different 
DOTAP concentrations, when added to lipid polymer hybrid nanospheres, affected cell 
viability of HEK293, HeLa, HaCaT, and HepG2 cells but  did not cause severe cytotoxicity > 
70 % cell viability (Bose et al. 2015).  However, our 15 % DOTAP NPs at 0.156 and 0.312 
mg/ml showed lower cell viability > 76 % in both A549 and calu-3 cell lines (Fig. 3–4C).  
The in vitro release profile of miRNA showed release of miR-146a from 15 % DOTAP NPs 
over 24 h which was similar to other in vitro release studies reported by other researchers 
 (Kumar et al. 2015, Sanna et al. 2012, Mohamed and van der Walle 2008). The miR-146a was 
adsorbed on 15 % DOTAP NPs via electrostatic interactions. The in vitro release curve 
suggests the weakly attached miR-146a was liberated rapidly over the first 4 h, while the 
remaining strongly attached miR-146a was slowly released between 4 h up to 24 h. This slow 
release rate of miR-146a is desirable in DDS to allow miR-146a cellular uptake (Huang and 
Brazel 2001, Jagani et al. 2013).   
Polymeric NPs are biodegradable under physiological condition, and PGA-co-PDL degrades 
slower than  PLGA when subjected to in vitro condition (Tawfeek et al. 2011). This particle 
degradation might affect the surface of particles over time, causing a change in miRNA release, 
similar to a study by Jagni et al.  where chitosan coated PLGA NPs were used  to adsorb siRNA, 
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which showed that particle degradation occurred over a period of time, affecting siRNA release 
and this particle degradation was influenced by particle surface charge and polymer 
hydrophobicity (Jagani et al. 2013).  
However, the in vitro release of miR-146a from 15 % DOTAP NPs is affected by the presence 
of DOTAP in NPs, cationic DOTAP has amine group that provide opportunity of 
intermolecular hydrogen bonding with PVA and PGA-co-PDL, so DOTAP forms a network 
on the particle’s surface which affects miR-146a release. Comparing our results with other 
studies that used adsorbed biomolecules such as siRNA, the in vitro release of siRNA from 
cationic PLGA was more than 60 % over 24 h (Jagani et al. 2013) whereas more than 70 % of 
our miR-146a was released from cationic NPs after 24 h. These biomolecules (siRNA and 
miRNA) and their potential in vitro release depends on the polymer hydrophobicity and the 
type of cationic material used, which is likely to result in a lower dose making it possible that 
this delivery system may also result in lower toxicity for the lung. The concept of using NPs 
as biomolecule or drug carrier for a specific targeting cells, the release of drug from particles 
influenced by surface modified particles  (Lin et al. 2001). Kunda et al. conducted a similar in 
vitro release study using PGA-co-PDL NPs adsorbed BSA protein, and found that more than 
90 % of BSA was released because of weaker hydrophobic interactions between BSA and NPs 
(Kunda et al. 2014a).  
 The in vitro release of miR-146a after 24 h was 77±1.5 %, which was the desired concentration 
for release and correlated with the change in gene silencing and protein levels in the Western 
Blot data, suggesting that miR-146a maintained its biological efficacy and was not affected by 
the degradation of NPs where protein level bands were intense at lower miR-146a-NPs 
concentration and the bands of intensity decreased when NPs concentration is increased. The 
difference in protein level bands show that miR-146a-NPs produce intense bands which 
indicates a slight decrease in protein level, whereas the less intense band caused a significant 
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decrease in protein levels, which will be discussed further in chapter 4, section 4.5.1. This 
suggests that miR-146a was successfully released from miR-146a-NPs within 24 h and was 
able to supress the gene expression. A similar study by Li et al. which used DOTAP as a 
cationic lipid to modify single-walled carbon nanotube as non-viral siRNA delivery system, 
found that cationic DOTAP electrostatically interact with negatively charged siRNA, 
protecting siRNA against degradation, siRNA was released from single-walled carbon 
nanotube-DOTAP and was able to fully realise its gene silencing potential in the cancer cells 
(Li et al. 2016a, Gibbings et al. 2009). 
miRNAs that have undergone clinical application have  shown the potential value of miRNA 
therapeutics,  for example, miR-34 for treating lung and prostate cancer, reached phase I 
clinical trial (Wiggins et al. 2010, Liu et al. 2011),  miR-208/499 for chronic heart failure (van 
Rooij et al. 2007) and miR-122 specifically for liver cancer, which has completed phase I and 
is currently in phase II  (Jopling et al. 2005).    
3.5.3 Cellular uptake  
Fluorescence and confocal microscopies are capable of imaging different cellular and 
molecular components  (Lichtman and Conchello 2005, Wang et al. 2012a) and allow for 
imaging fluorescently labelled cells and particles for greater depth of visualisation (Amos and 
White 2003). The rational for using two microscopes is that one microscope (fluorescence) can 
show cellular uptake as shown in Fig. 3–7 A, B and C, whilst the other (confocal) uses 
particular optical components to generate high-resolution 3-D images of material stained with 
fluorescent probes, to allow further uptake study in greater depth, to provide wider knowledge 
of co-localization and the interaction between NPs and cells as shown in Fig. 3–7 D, E and F. 
However, most of the research that has been conducted to study fluorescently labelled NPs and 
their interaction with cells using either microscopes  (Alfagih et al. 2015, Kunda et al. 2014b)  
or both of these microscopes (Böse et al. 2014, Xu et al. 1996, Win and Feng 2005).  Therefore, 
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applying these two valuable tools were used to determine the cellular uptake of NPs and nucleic 
acid loaded NPs.   
Conventionally, miRNA are very limited in their ability to cross the cellular membrane, without 
use of polymer based carrier DDS (Yin et al. 2014). The cationic NPs, with adsorbed miR-
146a, were distributed in perinuclear region in A549 lung fibroblasts. This distribution of FAM 
labelled miR-146a  suggest that miR-146a could interact with RISC complex with AGO2 and 
target mRNA in cytoplasm and achieve a good level of gene silencing (Wu et al. 2013b, Kuhn 
and Joshua-Tor 2013) .  
FAM-labelled miR-146a -NPs and NPs encapsulating Nile red dye were taken up by A549 and 
Calu-3 cells, which were used as model for alveolar and epithelial cells respectively. Nile Red 
NPs were used to show the ability of cationic NPs cellular uptake and to deliver miRNA to the 
cell. The uptake of polymer based NPs had previously been demonstrated in A549 (Kunda et 
al. 2015a),  dendritic cells (Alfagih et al. 2015, Kumar et al. 2012), breast adenocarcinoma 
MCF7 cells (Abulateefeh et al. 2013), liver cancer  cells, HepG2 and Hela cells (Díez et al. 
2009a), lung carcinoma cells, H1299 (Jensen et al. 2012, Howard et al. 2006b) and Chinese 
hamster ovary cells (Katas and Alpar 2006).  In the present study, NPs and FAM-labelled miR-
146a –NPs ended up successfully inside perinuclear region in both A549 and calu-3.  
The NPs were used in cellular uptake study were positively charged and in nano particle size 
(section 3.4.2). The surface charge and particle size, which are reflected by the zeta potential 
and dynamic laser scattering, influences NPs and helped in their cellular uptake (Stuart et al. 
2006). The particles in nanoscale size influence the cell interaction, a study by Jiang et al.  
showed the cellular internalization of Herceptin-gold NPs was size-dependant  (Jiang et al. 
2008) and this size can also  have implication on toxicity (Verma and Stellacci 2010, Nel et al. 
2009, Garnett and Kallinteri 2006). Moreover, the NPs’ surface charge contributes significantly 
to their interaction with cells, and the presence of cationic DOTAP facilitates the positively 
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particle surface interaction to negatively charged cellular membrane allowing NPs cellular 
uptake (Díez et al. 2009a). A study by Kedmi et al. showed the adjusted use of cationic DOTAP 
in the formulation improved NPs’ cellular uptake (Kedmi et al. 2010, Mukherjee et al. 2005).  
Moreover, it is notable that uptake and distribution of FAM labelled miR-1464a-NPs in cells 
that the NPs quantity is sufficient, indicating an active intracellular NPs transport, and miR-
146a reached perinuclear to initiate efficient gene silencing (Portis et al. 2010).    
3.6 Conclusion 
The cationic DOTAP was successfully used to produce cationic NPs with particle size 
244.8±4.4 nm which was similar to unloaded NPs 242.4±0.3 nm. Moreover, cationic NPs offer 
positive surface charge for miR-146a adsorption. The miR-146a adsorption was 32.25±2.0 µg 
miR-146a per 10 mg NPs after 2 h (the optimum conditions were 15 % DOTAP and miR146a 
adsorbed after 2 h). The in vitro release of miR-146a after 24 h was 77±1.5 %, the NPs were 
taken up by the cells and delivered miR-146a into the cell.  
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4. Evaluation of the miR-146a-NPs effect 
on target gene and protein expression 
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4.1 Introduction  
Based on the results of chapter 3, the optimum formulation had shown to successfully adsorb 
miR-146a on NPs, with low toxicity and uptake into cells. However, in this chapter we will 
investigate the functionality and activity of miR-146a from the optimum formulation. 
miR-146a has been associated with inflammatory pathway in the targeting of interleukin-1 and 
Toll-like receptor (TLR) signalling, of which NF-кB activation is a primary downstream 
effector, known as interleukin 1 receptor-associated kinase (IRAK1) and TNF receptor-
associated factor (TRAF6) (Taganov et al. 2006). Taganov et al. described  miR-146a as 
capable of controlling TLR and cytokine signalling through negative feedback regulation, with 
associated down regulation of IRAK1 and TRAF6 protein levels (Taganov et al. 2006). In 
addition, Bhaumik et al. reported that miR-146a showed  significantly downregulated IRAK1 
and TRAF6 in the IL-1 and TLR signalling pathway  (Bhaumik et al. 2008) using Western Blot 
to determine protein expression. Similar studies have been investigated with miRNA for 
inflammatory diseases through controlling signalling pathway. Sato et al. determined 
pathogenesis increase of the abnormal inflammatory cyclooxygenase (COX-2) half-life in 
chronic obstructive pulmonary disease (COPD) and enhanced production of prostaglandin E2, 
Quantitative Real- Time Polymerase Chain Reaction (qRT-PCR) assay was used to quantify 
miR-146a expression (Sato et al. 2010).  
 Post-transcriptional regulation of IRAK1 and TRAF6 by microRNA has been associated with 
the regulation of physiological responses as described by Perry et al. that showed the changes 
in expression of miR-146a could regulate the inflammatory response in human alveolar 
epithelial lung cells  (Perry et al. 2008). The miRNAs could be delivered to the site of action 
using nanocarriers, as a study by Wu et al. showed therapeutically delivered miR-29b in 
cationic lipoplexes for lung cancer in both in vitro using A549 cell lines and in vivo (Wu et al. 
2013c).  
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4.2 Aim 
The aim of this study was to determine the effect of miR-146a loaded NPs on IRAK1, TRAF6 
and protein expression.  
4.3 Methods 
4.3.1 Transformation and Quantification  
In order to assess direct interaction of miR-146a-NP with the 3’ UTR of IRAK1, a firefly 
luciferase plasmid reporter was used (Fig. 4–1) (Origene, UK).The plasmids were replicated 
in DH5-α Escherichia coli strain grown  on Luria-Bertani (LB) agar  supplemented with 
kanamycin at (10 µg/ml). After overnight incubation on the agar, a single colony was 
transferred into LB broth and incubated overnight at 37 °C. The bacterial cells were harvested, 
the plasmid isolated and purified by Qiagen plasmid maxi kit (Qiagen, UK) according to the 
manufacturer’s protocol. The Purified DNA was quantified by UV   spectrophotometry at 260 
nm and 280 nm (NanoDrop).  
The purified reporter plasmid was also characterized by (1 %) agarose gel electrophoresis. The 
agarose gel was run at 60–80 V for 60 min, lane for DNA ladder 200–10,000 bp as standards 
was used (HyperLadder, Bioline), and the DNA bands were visualized under UV light and 
photographed on a UV transilluminator (Syngene®, UK).  
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Figure 4– 1. pMirTarget vector map. Depiction of plasmid with firefly luciferase 
upstream of the 3’ UTR miRNA targeting sequence. Expression is driven by a simian 
virus SV40 promotor and translated with an internal ribosome entering sequence (IRES). 
Vector contains red fluorescent protein (RFP), kanamycin resistance gene and 
cytomegalovirus (CMV) (Jin et al. 2013, Petersen et al. 2006). 
 
 
 
3’UTR 
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4.3.2 Transfection and Luciferase assay 
Serum free Opti-MEM medium (Thermo Fisher, scientific, UK) was used for transfection of 
A549 cells seeded in 96-well white plates at a density of 2×105. After 24 h incubation, the cells 
were transfected with 100 ng 3’ UTR reporter plasmid (purified firefly luciferase plasmid 
reporter from section 4.3.1, Fig. 4–1). This vector has 3’UTR of IRAK1 which has two 
conserved binding sites for miR-146a and this 3’UTR was downstream of a firefly luciferase 
gene. The plasmid was designed with an SV40 promoter to drive constitutive expression of a 
selection marker (neomycin/kanamycin) fused to the firefly luciferase gene, with an IRES for 
translation of the luciferase transcript into protein. The exogenous miR-146a binding to the 
3’UTR should lead to a reduction in luciferase output. The vector has a region encoding RFP 
(driven by a CMV promoter) for validation of transfection by fluorescence microscopy. 
Plasmids encoding green fluorescent protein (pmaxGFP; Lonza) or encoding a red fluorescent 
protein endoplasmic reticulum marker (dsRed-ER; Clontech) were used as controls for 
transfection and fluorescence. Plasmids were combined with   0.15 or 0.3 µl Lipofectamine 
3000 reagent (Life technology) in Opti-MEM medium per well and incubated 6 – 48 h (37°C, 
5 % CO2 ) before removal of the complexes and further incubation with complete culture 
medium 24 – 48 h.  
Luciferase expression was performed using the luciferase assay system (Promega) according 
to the manufacturer’s protocol. Briefly, after 48 h incubation the medium was removed and the 
cells washed once with PBS, lysed by adding 20 µl lysis buffer. Then, 100 µl luciferase assay 
reagent was added. Luminescence was detected on a CLARIOstar® plate reader emission 
wavelength was adjusted at 580–80 nm to measure firefly luciferase activity. The luminescence 
values were represented as relative light units (RLU), also used red fluorescent protein (RFP) 
values for transfection monitoring and normalization. Fluorescence microscopy was used to 
visualise GFP and RFP expression.   
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4.3.3 Semi-quantitative reverse transcriptase RT-qPCR 
RT-qPCR was performed as described in section 2.4.  
4.3.4 miR-146a-NPs effect on protein expression 
Immuno western blotting is outlined as in section 2.5.  
4.3.5 IL-8 Promoter Reporter assay  
Cells were seeded on an 8 well chambered slide (Fisher Scientific, UK) at seeding density of 5 
× 105 cells per well and incubated for 24 h prior to transfection. Transfections were performed 
using lipofectamine 3000 reagent following the manufacturer’s protocol (Life technology, UK) 
in serum free DMEM and a total amount of 0.5 µg of DNA per well was used. The DNAs used 
were 213 - pIL8/d2EGFP and 269 - pDsRED mono promoters. The cells were transfected for 
6 h before removal of the mixture and washed twice with PBS. A prepared mixture of 
unlabelled miR146a-NPs (100 µl) was added and incubated for 1 h. After this time, the media 
was removed from cells and washed twice with PBS. Then, cells were stimulated with 1 ng/ml 
Interleukin beta and tumour necrosis factor-a (TNFα) and incubated for further 6 h. Cells were 
washed with PBS and subsequently fixed using ice-cold (-20°C) methanol. Images were 
acquired using an Olympus BX51 Fluorescent microscope.  
4.3.6 Statistical analysis  
All statistical analysis were performed using Minitab® 16 Statistical Software. One-way 
analysis of variance (ANOVA) with the Tukey’s comparison was employed for comparing the 
formulations with each other. Statistically significant differences were assumed when p<0.05.  
Statistical analyses were performed in GraphPad Prism 5 (GraphPad Software, Inc., San 
Diego,CA). All values are expressed as their mean ± standard deviation (SD). 
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4.4 Results  
4.4.1 Effect of miR-146a-loaded NPs on target gene expression 
To confirm miR-146a function after adsorption onto the NPs, the expression of target genes 
IRAK1 and TRAF6 was assessed in A549 cells. Analysis of transcript levels showed that miR-
146a delivered via NPs (miR-146a mimic) led to dose dependent suppression of IRAK1 (Fig. 
4–2) and TRAF6 (Fig. 4–3) compared with untreated cells. The expression of IRAK1 and 
TRAF6 was normalised to GAPDH expression. The average of all concentrations was pooled 
from three independent experiments (Appendix–1 and Appendix–2).  
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Figure 4– 2. Effect of miR-146a loaded NPs on IRAK1 expression. Data were pooled from 
three independent experiments (A, B & C). The highest two concentrations are shown at 
(D) were pooled from the three independent experiments. The expression of IRAK1 was 
normalised to GAPDH expression. Values in graph D are Mean ± SD (n=3). 
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Figure 4– 3.  Effect of miR-146a loaded NPs on TRAF6 expression. Three independent 
experiments (A, B & C). Lowest two concentrations (D) were pooled from the three 
independent experiments. The expression of TRAF6 was normalised to GAPDH 
expression. Values in graph D are Mean ± SD (n=3). 
 
 
 
 
 83 | P a g e  
 
4.4.2 Effect of miR-146a-loaded NPs on protein expression 
To confirm the downregulation of IRAK1 and TRAF6 occurred at the protein levels, miR-146a-
loaded NPs were applied to A549 cells and lysates evaluated by immunoblotting. As shown in 
Fig. 4–4, the miR-146a-NPs reduced IRAK1 protein levels in A549 cells after 24 h and 48 h 
treatment. The decrease in protein levels occurred in a dose dependent manner compared to 
untreated cells, suggesting that IRAK1 protein levels reduced in response to miR-146a-NPs.  
 
 
 
Figure 4– 4. Effect of miR-146a on IRAK1 protein levels in A549 cells. Dark triangle 
represents lowest (left) to highest (right) miR-146a-NPs concentrations. The numbers 
under each band represents the densitometric readings relative to control samples that 
are normalized to each band and to its corresponding β -actin control.  
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4.4.3 Transfection and Luciferase assay 
To assess miR146a-NPs biological function, A549 cells were transfected with  luciferase using 
lipofectamine 3000 as a transfection reagent with purified plasmid to identify the transfection 
toxicity and effectivity. However, when Lipofectamine 3000 was used, it did not cause any 
transfection with a longer incubation time of more than 6 h (Fig. 4–5). After 24 - 48 h of 
incubation, the A549 cells died despite using different cell densities of 10,000 and 12,000 cell 
per well which is in line with other studies indicating the toxic behaviour of Lipofectamine 
3000 (Zhong et al. 2008). Therefore, the incubation period of 6 h is considered as the optimum 
incubation time for Lipofectamine 3000.  
 
 
 
 
 
 
 
 
 
Figure 4– 5.  Shows the effect of transfection reagent (Lipofectamine 3000) on A549 cells 
after incubation at different time points (A) un-transfected cells 24 h, (B) transfected and 
incubated for 6 h (C) after 24 h transfection. 
 
A B C 
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Further analysis of transfection reagent toxicity, with Lipofectamine 3000 was carried out on 
A549 cells with different concentrations to transfect plasmid. The fluorescence images in Fig. 
4–6A, B and C, showed a transfection expression occurred in GFP and ds-Red. However, there 
was no expression detected of RFP despite the same procedure followed with the GFP and ds-
Red. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4– 6. Fluorescence images of fixed A549 cells.  Expression (A) GFP,   (B) RFP and 
(C) dsRed-ER. The scale bars represent 20 µm. 
 
Gel electrophoresis was used to find the presence of plasmid. The results in Fig. 4–7 showed 
that the presence of plasmid and purity of plasmid also have been confirmed 
A B C 
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spectrophotometrically by NanoDrop that determined A260/280 ratio and the concentration 
was within a ratio of 0.1 – 1.  
 
 
 
 
 
 
 
 
 
 Figure 4– 7. Gel electrophoresis of plasmid after purification using Qiagen plasmid maxi 
kit.  The left band shows the marker and the right band represents pure plasmid (7.9 bp). 
 
4.4.4 Reporter assay  
To determine miR-146a-NPs biological function, the IL-8 promoter reporter assay was used. 
The pIL-8 promoter- GFP reporter was transfected into A549 cells, which are noted to express 
the functional IL-1 receptors (Ding et al. 1998). The promoter’s response after IL-1β 
stimulation produced an intense fluorescent signal Fig. 4–8A, while IL-8 promoter reporter 
output (GFP) was dampened by miR-146a-NPs Fig. 4–8B. 
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Figure 4– 8.  Fluorescence images of (A) response of pIL8 reporter to cells stimulated 
with IL-1β, (B) Cells loaded with miR-146a-NPs prior to stimulation with IL-1β. The scale 
bar represent 20 µm.  
 
4.5 Discussion 
4.5.1 Functional evaluation of miR-146a loaded NPs  
To confirm the functional activity of miR-146a loaded NPs, their impact was assessed on two 
leading miR-146a target genes, IRAK1 and TRAF6. A study by Taganov et al. indicated that 
miR-146a inhibit the expression of  IRAK1 and TRAF6 genes and the significant function of 
miR-146a as negative regulator of inflammation  (Taganov et al. 2006).  The responses varied 
across the three independent experiments performed in each case but reduced expression of the 
IRAK1 (Fig. 4–2) or TRAF6 transcripts was observed in response to most doses (Fig. 4-3). This 
suggest that NPs delivered miR-146a to site of action and produced the expected 
downregulation effect. However, the highest NPs concentrations (Fig. 4–2D), reduced target 
A B 
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gene IRAK1 expression to 40 %. The highest NPs concentrations were used as an overall 
average, as they showed a very strong downregulation effect compared with the lowest NPs 
concentrations. In the case of TRAF6 the lowest NPs concentration (Fig. 4–3D) caused the 
expression to be reduced to over 20 %. The lowest NPs concentrations were used as overall 
average, as they showed a very strong downregulation effect compared with the highest NPs 
concentrations. Thus, low doses of miR-146a-NPs appeared to be more effective at 
downregulating TRAF6 than IRAK1.  
TRAF6 has three conserved miR-146a binding sites in the 3’UTR of mRNA and IRAK1 has 
two conserved sites in the 3’UTR. This suggests that miR-146a-NPs downregulated the TRAF6 
target gene more than IRAK1. There are computational algorithm programmes that provide a 
valuable resource in predicting the biological target of miRNAs in relation to gene regulatory 
networks. The TargetScan programme was used to predict conserved sites for miRNA with 
their target regions (Agarwal et al. 2015). Assessment of the impact of the miR-146a-NPs on 
IRAK1 and TRAF6 protein levels revealed understanding the effect of miR-146a-NPs (Fig. 4–
4). However, protein band intensity decreased when the NPs’ concentration is further 
increased. Thus, it is clear that miR-146a delivery using NPs dependent on miR-146a and NPs 
amount, which indicates the capability of miR-146a loaded NPs ability to control COPD 
disease.  
To determine the difference in IRAK1 expression, and whether the miR-146a-NPs influenced 
protein of interest in lung cell lines. As presented in the results (Fig 4–4), anti-IRAK1 antibody 
appear to bind specifically to the protein of interest. This is in agreement with the results of 
Chen et al. where the anti-IRAK antibody was suitable for WB  (Chen et al. 2012).  
There was no significance difference found between 24 h and 48 h after miR-146a-NPs 
treatment, suggesting that treatment with as little as miR-146a-NPs concentration  were enough 
to exhibit the maximum targeting capacity of cellular environment (Ghosh et al. 2013, Song et 
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al. 2006b), affecting IRAK1 protein levels the physiological pathway (Taganov et al. 2006). 
However, TRAF6 protein expression was not tested, and whether the miR-146a-NPs influenced 
this protein in the lung cell lines we don’t know, but we expect the same modulation as IRAK1 
protein expression in these cell lines, which was confirmed by the functional activity of miR-
146a loaded NPs which inhibit the expression of TRAF6 genes. These functional studies 
confirm that miR-146a-NPs delivered to site of action in the lung cell lines, and miR-146a have 
modulated both genes and protein levels (Ezzie et al. 2011). With these results, miR-146a-NPs 
appeared to be a promising therapeutic approach for treatment of disease by targeting genes 
that involved in unusual pathological way.   
The NPs have played important role in terms of delivery  DNA into dendritic cells and protected 
the DNA from degradation (Yuba et al. 2008). However, miR-146a molecules without delivery 
carrier are rapidly affected by enzymes activity in lung airways  (Takei et al. 2004). Although 
intratumoural injection of Let-7 miRNA into tissue can reduce tumour distribution with some 
limited therapeutic potential, however, miRNA delivery using delivery carrier could 
significantly improve the gene knockdown (Wiggins et al. 2010).  
4.5.2 Transfection and Luciferase assay 
 
 The expression occurred in GFP and dsRed-ER in the transfected cells (Fig. 4–6A and C). 
These two have small size plasmids of approximately 4.7 kb while RFP plasmid size has 7.9 
kb and its expression was not detected (http://www.origene.com/MicroRNA/3-UTR-Clone/). 
The use of luciferase RFP reporter was designed to monitor the transfection and interaction 
with 3’UTR miRNA. Tanganov et al. used luciferase reporter to show the role of miR-146a 
and its target in 3’ UTRs of IRAK1 and TRAF6  (Taganov et al. 2006). Our experimental design 
was to transfect the GFP, dsRed-ER and RFP into lung cell lines (Fig. 4–6A, B and C).  
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If any marked fluorescence in the reporter’s expression were expected, the miR-146a-NPs 
would have been used to determine the expression. Kumar et al. used a fluorescence reporter 
to identify siRNA inhibition of target gene using enhanced GFP and RFP. There was a 
significant reduction in enhanced GFP but not in RFP expression (Kumar et al. 2003). Our data 
indicated there was no expression detected for the required RFP in A549 cell line. 
Consequently, then 3’ UTR luciferase reporter will not be reliable and due to limited funding 
available for the continuation of this project Luciferase assay was not further tested on miR-
146a-NPs. 
4.5.3 Reporter assay 
 
To determine the effect of miR-146a-NPs in the expression of target genes IRAK1, protein 
levels, pIL-8 promoter reporter assay was used. The pIL-8 promoter-GFP reporter was 
stimulated with proteins noted to be involved in IL-1β signalling (Fig. 4–8). The IL-1β has the 
ability to stimulate IRAK1 phosphorylation in cytoplasm of A549 cells. The phosphorylated 
IRAK1 is associated with TRAF6, and this association activates the ligase function of TRAF6 
leading to ubiquitin-mediated activation of NF-кB in Toll-like receptor (TLR) signalling (Bhoj 
and Chen 2009). Kiss-Toth et al. have described the protein functional expression from pIL-8 
promoter that was induced by IL-1 and tumour necrosis factor TNF-α which underlined the 
physiological inflammatory response of the given promoter (Kiss-Toth et al. 2000).  However, 
miR-146a was shown to be involved in targeting of the IL-1 and TLR signalling involving NF-
кB, IRAK1 and TRAF6 (Taganov et al. 2006, Bhaumik et al. 2009). Perry et al. have determined 
the miR-146a action mediated through regulation of proteins involved in IL-1β signalling 
pathway and showed that the changes in expression of miR-146a can regulate the inflammatory 
response in human alveolar epithelial lung cells (Perry et al. 2008). When miR-146a-NPs were 
delivered to A549 cells prior to IL-1 stimulation, this led to a decrease in the fluorescence 
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intensity. As such, miR-146a-NPs’ delivery to cytoplasmic target proteins and regulated 
biological inflammatory process is based on the functional GFP expression which is in line 
with other studies indicating the biological process  (Kiss-Toth et al. 2000, Bhoj and Chen 
2009, MacKenzie et al. 2001).  
4.6 Conclusion 
The miR-146a maintained its functional structure under gene silencing and protein level. The 
high miR-146a-NPs concentration reduced target gene IRAK1 expression to 40 % and TRAF6 
the lowest NPs concentration reduced to over 20 %. We have showed that the optimum 
transfection reagent incubation period of A549 cell is 6 h. The GFP and dsRed expression occur 
in A549 cells.  The miR-146a-NPs reduced IL-8 promoter reporter GFP via IL-1β signalling 
pathway suggestion that miR-146a-NPs can be used to target proteins, regulate the 
inflammatory process. These successful studies and results show the potential of cationic NPs 
for delivery of miR-146a in the treatment and management of COPD. These results can allow 
further research on these NPs to be nanocomposite microparticle and form potential spray dry 
powder and evaluate the cellular functionality.  
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5. Formulation of Dry Powder 
Nanocomposite Microparticles (NCMPs) 
for pulmonary delivery 
 
 
 
 
 
 
 93 | P a g e  
 
5.1 Introduction 
The treatment of COPD by inhalation to the lungs has emerged as an attractive alternative route 
to oral dosing due to higher concentrations of the drug being administered to a site of action 
avoiding degradation by the strong acids and enzymes in the oral route. The nanoparticles 
(NPs) delivered to the lungs for pulmonary drug delivery essentially require an appropriate size 
that allows the small nucleic acid reach to the target site and correct the faulty genes. In fact, 
NPs in the dry powder form do not deposit efficiently in the alveolar part of the lungs, which 
results in the exhalation of the majority of the inhaled dose (Sung et al. 2007). However, the 
ideal particle size for optimal particle deposition in the deep lung ranges from between 1 to 5 
µm in diameter (Sakagami 2006). Therefore, NPs can be incorporated into dry powder 
microparticles (NCMPs) of aerodynamic particle size 1-5 µm   through spray drying (Alfagih 
et al. 2015).  Spray drying is a  one step process that converts liquid  solution  or suspension to 
dry powder, which are designed to diffuse in the lung lining fluid and release its contents  
(Ungaro et al. 2012). The spray drying process is controlled by different parameters to provide 
desirable particle size and aerosolisation properties (Sakagami 2006). It is important to take 
into consideration, when designing an experiment that aims to determine the influence of 
various parameters on the properties of the dosage formulation being studied and these 
parameters  optimized in order to obtain  desirable results (Yang and Zhu 2002). Liang et al. 
have prepared a powder formulation using pH responsive peptides for influenza treatment, and 
it was found that the integrity and  biological activity of siRNA were well preserved after spray 
drying (Liang et al. 2015).  
Moreover, excipients such as sugars and amino acids can be added to the formulation resulting 
in changes to physical characteristics of powders, including the morphology, moisture content, 
particle size and density (Bosquillon et al. 2001). The selection of appropriate excipients for 
inhalation leads to optimal and functional dry powder formulation, can help preserve NPs and 
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nucleic acid integrity. It is important to maintain NPs integrity that allows recovery of NPs 
size, can cross biological barriers e,g lung lining fluid and be up taken by cells. If particle 
aggregate and become larger can impact on diffusing through lung lining fluid and uptake by 
cells hence reducing miRNA uptake into cells.  
L- Leucine is one of the amino acids that has been used as a cryoprotectant and dispersing 
agent that improves aerosolisation properties for dry powders, reduces contact cohesion 
between the particles and prevents aggregation (Alfagih et al. 2015, Tawfeek et al. 2011, Cruz 
et al. 2011, Lucas et al. 1999, Rabbani and Seville 2005, Kunda et al. 2015a). L-leucine is 
considered as a hydrophobic amino acid that accumulates at the air water interface (Vehring 
2008). Sugar excipients such as mannitol are commonly used in spray drying with good safety 
characteristics, are less hygroscopic than lactose, have muco-adhesive properties and they have 
European approval for dry powder inhalation (Jensen et al. 2010, Pilcer and Amighi 2010, 
Burness and Keating 2012).   
Furthermore, different forms and ratios of amino acids and sugars can be used alone or as a 
combination in the same formulation which produces positive results. You et al. performed a 
study using the  spray drying method by mixing amino acids (L-leucine, glycine and threonine)  
and sugars (trehalose, lactose, dextran and mannitol) , which resulted in these excipients having 
affected the dry powder flow rate, aerosolisation behaviour, median aerodynamic diameters, 
moisture content and yield (You et al. 2007).   
Similarly, these excipients can protect, and stabilize the NPs and encapsulated materials against 
the intense spray-drying process including operational high temperature and mechanical stress 
(Alfagih et al. 2015).  In addition, excipients added to the spray dried formulations induce the 
production of a desirable aerodynamic particle size 1-5 µm  and release of the active ingredients 
after they decompose in the lung lining fluid  (Jensen et al. 2010, Saluja et al. 2010). Taking 
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into account the advantage of the promising biological effects of inhaled siRNA in the lung 
there has been very limited work exploring miRNA spray drying. In this chapter, L-leucine and 
mannitol were mixed together as dispersion enhancer and protective excipients. L- Leucine 
was chosen due to cryoprotectant, dispersing properties and high aerosolisation properties 
(Alfagih et al. 2015, Tawfeek et al. 2011), whereas mannitol was chosen owing to its mucho-
adhesive properties, the fact it is a protective excipient for small nucleic acids, and its good 
safety characteristics and European approval for dry powder inhalation (Jensen et al. 2010, 
Pilcer and Amighi 2010, Bhowmik et al. 2009). This is the first time that miRNA was 
formulated into inhalable dry powder using a mix of amino acid and sugar excipient.   
5.2 Aim 
 
The aim of this chapter was to optimise the production of NCMPs of miR-146a-containing 
PGA-co-PDL NPs for dry powder inhalation in terms of size, morphology, aerosol 
performance, moisture content and miRNA functionality.  
To obtain the aim of the study, the following objectives were considered;  
1. Formulation of NCMPs via spray-drying technique and evaluating;   
a. The influence of L-leucine to mannitol ratio on the NPs recovery size and yield %. 
b.  The influence of spray drying parameters on morphology, aerosol performance, 
and moisture content of NCMPs. 
2. Determining the impact of biological activity of miR-146a loaded NCMPs.  
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5.3 Methods  
5.3.1 Preparation and characterisation of NPs and miRNA adsorption  
PGA-co-PDL NPs were prepared and miRNA adsorbed as described in section 2.2. 
Characterisation of PGA-co-PDL NPs and miRNA adsorption were performed as described in 
section 2.3. The optimum NPs formulation used for NCMPs.  
5.3.2 Preparation of Nanocomposite Microparticles  
The NCMPs preparation were conducted in Department of Pharmaceutical Technology, 
Faculty of Pharmacy with Associate Prof Dr Ayca Yildiz Pekoz during my Erasmus exchange 
at Istanbul University May-July 2016. The NCMPs were prepared by spray drying the NP 
suspension from  different aqueous solutions containing L-leucine and mannitol in various 
ratios (F1; 100:0 % w/w, F2; 75:25 % w/w, F3; 50:50 % w/w, F4; 25:75 % w/w, F5; 0:100 % 
w/w),  with a NP to micro carrier ratio of 1:1.5 w/w (Alfagih et al. 2015) using a Büchi B- 290 
mini spray-dryer (Büchi Labortechnik, Flawil, Switzerland) using the conditions of 
experimental design (section 5.3.3). The optimised condition used for  spray drying was 
performed at feed rate 0.5 ml/min, aspirator capacity 70 %, atomizing air flow rate 480 L/h, 
inlet drying temperature 70 ºC (corresponding outlet temperature of approximately 47 ˚C). Dry 
particles were separated from the airstream by centrifugal forces using a high-performance 
cyclone (Büchi Labortechnik) (Fig 5–1), collected and stored in desiccator at room temperature 
until further use. 
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Figure 5–1 Diagram illustrates miRNA-NPs incorporated NCMPs.  
 
5.3.3 Experimental design  
The experimental design of the current formulation was optimized according to previous 
laboratory work and pre-formulation studies (Alfagih et al. 2015), combined with further 
parameters from the literature (Jensen et al. 2012, Edwards et al. 1998, Ståhl et al. 2002). It 
was composed of five variables and four levels (Table 5–1). The rational for using different 
parameters and levels is that some parameters were used for preparing protein loaded PGA-co-
PDL NCMPs using L-leucine, but these parameters for example use high temperature, which 
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would damage miR-146a biological functionality. However, it was combined with further 
parameters derived from the literature that have used mannitol for siRNA and DNA, assuming 
that that will not affect miR-146a. The use of mannitol also preserves the biological activity 
and identifies the influence of spray drying parameters on recovered NPs size and yield %.   
Table 5– 1. Nanocomposite microparticles process variables  
Parameters Unit Level 1 Level 2 Level 3 Level 4 
Feed Rate ml/min 0.3 0.5 1 1 
Atomized air flow L/h 480 480 400 400 
Aspirator capacity % 70 70 100 100 
Inlet temperature °C 45 70 100 75 
Approximate Outlet 
temp 
°C 30 47 75 60 
 
5.3.4 Characterisation of Nanocomposite Microparticles 
The NCMPs characterisation were conducted in International Turkish pharmaceutical 
company- DEVA with assistance from Prof Dr Ayca Yildiz Pekoz during my Erasmus 
exchange at Istanbul University. 
5.3.4.1 Yield  
The dry powder yield was determined as the percentage mass of expected powder (n=3) 
according to following equation:   
Yield % = 
weight of powder collected after spray drying 
 weight of total dry mass used for the preparation
× 100    
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5.3.4.2 Morphology  
The spray dried powder was examined using a scanning electron microscope (SEM), Quanta 
450, FEI, Oregon, USA). The spray dried samples were mounted on an aluminium stub with 
adhesive, coated with gold (40–60 nm) and then observed at high vacuum.  
5.3.4.3 Particle size  
NCMPs (2 mg) were re-dispersed in 4 ml water to release the NP. The NP size was measured 
as described in section 2.3.1.   
5.3.4.4 Moisture content  
The water content of the NCMPs powder was determined by thermogravimetric analysis 
(TGA), using a Linseis STA PT 1750 Model Thermo Anaylzer system, Germany. NCMPs 
powder (10 mg) was heated between 25 °C to 650 °C at constant rate 10 °C/min in nitrogen 
gas. The weight loss (%) due to water evaporation, was recorded between 25 °C and 120 °C.  
5.3.4.5 Powder density and Aerodynamic diameter  
The Tapped density of the NCMPs was determined by adding approximately 0.2 g of powder 
to a 5 ml measuring cylinder. The initial bulk volume (Vo) was recorded and then again 
following mechanical tapping ten times (V10), then five hundred times (V500), then after one 
thousand and two hundred fifty (V1250) taps until no reduction in the particle volume was 
noticed. The theoretical aerodynamic diameter (𝑑𝑎𝑒) was determined based on the data 
obtained from geometric particle size (𝑑) and tapped density (𝑝). 𝑝1  is the unit density (1 
g/cm3)                                
                             
𝑑𝑎𝑒 = 𝑑√
𝑝
𝑝1
                                                                              (Sou et al. 2011) 
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5.3.4.6 Flowability and Carr’s index 
The particle flowability was analysed by Carr’s index (compressibility index) and the 
Hausner ratio, using the values obtained for bulk density (Ρ bulk) and tapped density (Ρ tapped) 
(Louey et al. 2004) as follow;  
Compressibility Index = 
𝚸 tapped− 𝚸 bulk  
𝚸 tapped
× 100 
 
Hausner Ratio = 
𝚸 tapped  
𝚸 bulk
                                                                  
5.3.4.7 In vitro aerosolisation studies  
The aerosol performance of the NCMPs was evaluated using a next generation impactor (NGI). 
The powder (10mg) was manually loaded into each of four hydroxypropyl methylcellulose 
HPMC size 3 (Qualicaps, Japan). The capsules were pierced by a needle pierce using a 
Cyclohaler® (Teva pharma) and aerosolised into the NGI that was connected to a pump 
(Copley Scientific, UK). The airflow was measured and adjusted prior to every experiment by 
using a flow meter (Copley Scientific, UK). The flow rate was operated at 60 L/min for 4 
seconds. The plates were coated with polyethylene glycerol (PEG-200) to decrease powder 
bounce (Edwards et al. 1998). The amount of particles deposited in each stage of the impactor 
was evaluated gravimetrically by measuring the difference in mass before and after powder 
deposition (Meenach et al. 2013a, Meenach et al. 2013b). The effective cut-off diameter for 
each impaction stage was calibrated by manufacturer and stated as shown in Table 5–3 (Hess 
2005, Wu et al. 2013a). The fine particle dose (FPD) defined as the mass of the drug deposited 
in the NGI with dae < 4.46 μm, fine particle fraction (FPF %) is the fraction of emitted dose 
deposited in the NGI with dae < 4.46 μm, respirable fraction (RF) is the mass of particles < 4.46 
μm and emitted dose (ED) is the amount of drug exiting the inhaler.  
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Table 5– 2. The effective cut-off diameter for NGI impactor at 60 L/min 
Stage cut-off diameter (µm) 
1 8.06 
2 4.46 
3 2.82 
4 1.66 
5 0.94 
6 0.55 
7 0.34 
 
 
The fine particle dose (FPD), fine particle fraction (FPF), respirable fraction (RF), and emitted 
dose (ED) were calculated as;  
 
Fine particle dose (FPD, mg) = mass of particles < 4.46 µm (stages 2 through 7)   
 
Fine particle fraction (FPF %) = 
Fine particle dose  
initial particle mass loaded into capsules 
× 100% 
 
Respirable fraction (RF %) = 
Mass of particles < 4.46 µm (stages 2 through 7)
Total particle mass on all stages 
× 100% 
 
Emitted dose (ED %) = 
Initial mass in capsules - final mass remaining in capsules  
initial mass in capsules 
× 100 
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The mass mean aerodynamic diameter (MMAD, µm) and geometric standard (GSD, µm) 
were calculated from log probability analysis using the following website 
(http://www.mmadcalculator.com/).  
5.3.5 Effect of miR-146a-NCMPs on target gene and protein expression  
The prepared optimum miR-146a-NPs in section 2.2 were spray dried as described in section 
5.3.2 and biological functionality determined through semi-quantitative reverse transcriptase 
RT-qPCR and Western blot as described in section 2.4 and 2.5 respectively.  
 5.3.6 Statistical analysis  
All statistical analysis were performed using Minitab® 16 Statistical Software. One-way 
analysis of variance (ANOVA) with the Tukey’s comparison was employed for comparing the 
formulations with each other. Statistically significant differences were assumed when p<0.05. 
Statistical analyses were performed in GraphPad Prism 5 (GraphPad Software, Inc., San 
Diego,CA). All values are expressed as their mean ± standard deviation (SD). 
5.4 Results   
5.4.1 Spray drying optimization  
Process parameters (Table 5–1)  adopted from  (Alfagih et al. 2015), for L-leucine NCMPs 
were applied alongside published  parameters related to mannitol (Jensen et al. 2012), to 
identify the influence of spray drying parameters on NPs size and yield % (Table 5–3). The 
recovered NPs had sizes ranging from 175.93 nm to 3252.06 nm and a yield from 20.80 % to 
96.00 % was obtained (Table 5–3). Based on the recovery of the NPs’ size, yield (Table 5–5) 
response, and spray drying outlet temperature of 47 °C, Level 2 parameters were chosen to be 
applied further. 
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Table 5– 3.  Nanocomposite microparticles different levels Influence on particle size and 
yield. 
  Excipient Response 
 Formulations Leucine 
(%) 
Mannitol 
(%) 
Yield 
% 
Recovery 
of NPs 
size (nm) 
 
 
Level 1 
 
F1 100 0 20.80 251.06 
F2 75 25 Non Non 
F3 50 50 84.80 289.80 
F4 25 75 48.00 175.93 
F5 0 100 76.00 319.13 
 
 
Level 2 
F1 100 0 64.00 774.26 
F2 75 25 86.40 1373.33 
F3 50 50 93.60 823.13 
F4 25 75 96.00 327.96 
F5 0 0 85.60 992.53 
 
 
Level 3 
 
 
F1 100 0 36.00 958.30 
F2 75 25 84.00 1810.66 
F3 50 50 91.20 3252.06 
F4 25 75 86.40 471.64 
F5 0 100 80.80 2174.60 
 
 
Level 4 
 
 
F1 100 0 36.00 669.10 
F2 75 25 84.00 600.90 
F3 50 50 91.20 747.10 
F4 25 75 86.40 297.10 
F5 0 100 80.80 682.40 
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5.4.2 Moisture content, powder flow and Carr’s index 
Water content for formulations (F1–F5) were within the range of moisture content 
( 2.02±0.03 % – 5.1±0.37 %) of spray-dried particles intended for lung deposition (Ståhl et al. 
2002, Chew et al. 2005a), (Table 5–4). However, F4 had the lowest moisture content, due to 
the presence of a higher percentage of mannitol (Jensen et al. 2012). 
To measure flow properties of NCMPs, Carr’s compressibility index was used and determined 
from tapped and bulk density (Table 5–4). Values of more than 25 % indicated poor 
followability (Learoyd et al. 2008).  
Table 5– 4. Physical properties of spray-dried nanocomposite microparticles. Mean± SD 
(n=3). 
Formulations Tapped 
density 
(g/cm3) 
Water 
content  
(%) 
Carr’s 
Index 
Hausner 
Ratio 
Flow 
character 
F1 (-) 5.1±0.37 N/A N/A N/A 
F2 0.17±0.01 4.91±0.20 33.30 1.30 Poor 
F3 0.13±0.20 3.8±0.90 0 ( ≤10 ) 1.00 Excellent 
F4 0.14±0.01 2.02±0.03 33.30 1.30 Poor 
F5 0.20±0.05 3.77±0.11 66.60 1.60 V. Very poor 
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5.4.3 In vitro aerosolisation studies 
The in vitro aerosol dispersion properties of NCMPs were determined using NGI.  The mass 
mean aerodynamic diameters (MMAD) ranged from 4.20±0.15 to 6.03±1.08 µm. The NCMPs’ 
formulations (F1-F4) showed that MMAD was less than 6 µm except F5 which was 
significantly greater 6.03±1.08 µm (p<0.05, ANOVA/Tukey’s) (Fig. 5–2B). The 
corresponding geometric standard deviation (GSD) values were approximately similar in size 
from 1.75± 0.31 – 2.15±0.53 µm.  
 FPF % showed that F4 produced significantly higher FPF % (51.33±2.90 %) compared to the 
other formulations (p<0.05, ANOVA/Tukey’s). The highest FPF % means the best 
aerosolization characteristics in term of deposition.  The presence of leucine weight ratio to 
mannitol ratio in F4 resulted in high FPF compared to F1, which has no mannitol. Moreover, 
the incorporation of leucine into formulations has increased FPF %. F4 has 25 % leucine which 
resulted in more than double values of FPF %, 51.33±2.9 % and FPD, 20.53±2.90 mg 
respectively compared to F5, 0 % leucine with FPF %, 19.96±1.2 % and FPD 7.98±1.2 mg 
(Fig. 5–2A and Fig. 5–2E). The ED values were all over 50 % with highest value for F4 
81.81±3.0 % (Fig. 5–2D). 
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Figure 5– 2. (A) The percentage fine particle fraction spray dried powder (B) mass mean 
aerodynamic diameter (µm).  (C)  Respirable fraction percentage. (D) Emitted dose. (E) 
Fine Particle Dose. Data represent mean ±SD (n=3), (*p<0.05, ANOVA/Tukey’s).  
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5.4.4 Recovered particle size and yield 
From Table 5–3, Level 2 is the best in terms of yield percentage (Level 2, 96.00 % of dry 
powder compared with other level 3, 86.40 %) and recovered size of NPs (where level 3 has 
high NPs size after recovery), of which F4 is the optimum and taken forward, based on results 
of moisture content, powder flow (section 5.4.2), and aerosolisation data (section 5.4.3).  The 
results of the recovery of F4 NPs’ size and yield percentage were repeated to gain more 
replicates as shown in (Table 5–5). The particle size for all the levels and formulations were 
different, however, the smaller particle size recovered after spray drying was preferred and 
needs to be similar to prior spray drying (Alfagih et al. 2015).   
Table 5– 5. Optimum Spay dried particles size and yield. Mean± SD (n=3). 
 Particle size (nm)  
Formulation Before spray 
drying 
After spray  
drying 
Yield % 
F4 244.8±4.40 409.7±10.05 86.0±15.01 
 
5.4.5 Morphology, Powder density and Aerodynamic diameter of 
formulation F4 
The formulated NCMPs (F4) were analysed for shape and morphology using SEM (Fig. 5–3) 
and micrographs showed that NCMPs possessed a spherical shape and corrugated surface. The 
tapped density of PGA-co-PDL NCMPs varied between 0.132±0.03 to 0.20±0.01 g cm-3, and 
F4 0.14±0.01 g cm-3 (Table 5–4). The Geometric particle size and tapped density was then used 
to calculate the theoretical dynamic diameter (dae). The optimum formulation (F4) dae was 
0.63±0.01 µm.  
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Figure 5–3.  SEM images of F4 NCMPs, the scale bars represent 5 µm and 10 µm. 
 
5.4.6 Effect of miR-146a-NCMPs on target gene and protein expression 
To confirm miR-146a-NCMPs biological functionality after spray drying, the expression of 
target genes IRAK1 and TRAF6 was assessed in A549 cells. Analysis of transcript levels 
showed that miR-146a expression against targeted genes IRAK1 and TRAF6 (Fig. 5–4). The 
expression of IRAK1 and TRAF6 was normalised to GAPDH expression. These results were 
comparable with the miR-146a-NPs data that was mentioned in section 4.4.1.  
In Western Blot, miR-146a reduced IRAK1 protein levels in A549 cells after 24 h and 48 h 
treatment. The β-actin was used as control. As shown in (Fig. 5–5), the protein level decreased 
in a dose-dependent manner compared to untreated cells.  This suggested that IRAK1 protein 
levels were reduced in response to miR-146a-NCMPs.  
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Figure 5– 4.  MiR-146a-NCMPs reduce miR-146a target expression. Levels of IRAK1 and 
TRAF6 were assessed by sqRT-PCR in A549 cells that had been exposed to miR-146a-
NPs or miR-146a-NCMPs for 1 h washed then incubated for 24 h. The doses yielding the 
most consistent downregulation of the target genes are shown. Mean ± SD (n=3). 
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Figure 5– 5. Western Blot expression of miR-146a reduced IRAK1 protein levels in A549 
cells for 24 h and 48 h. Dark triangle represents lowest (left) to highest (right) miR-146a-
NCMPs concentrations. Numbers under each band represent the densitometric readings 
relative to control samples that normalized each band to its corresponding β -actin 
control.  
 
5.5 Discussion  
5.5.1 Optimization of spray drying process  
The spray drying optimisation process was utilised to incorporate NPs into NCMPs using 
different ratios of L-leucine and mannitol excipients. From Table 5–3, it can be seen that all of 
levels (1–4) had variable yield % and NPs recovered particle size results.  The different spray 
drying parameters (Table 5–1) were used to identify the best level that preserved the recovered 
particle sizes and produced the highest yield % during the spray drying process. Generally, 
levels 1, 3 and 4 produced acceptably high yields as a % and large particle size. However, Level 
2 showed the highest yield  96.00 % accompanied with the smallest particle size < 500 nm 
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(Table 5– 2), which would maintain miRNA biological functionality. Spray drying parameters 
used in level 2 showed, that outlet temperature 47 °C (Table 5–1) was below melting point of 
PGA-co-PDL NPs (Tawfeek et al. 2011, Tawfeek et al. 2017).   Monitoring and maintaining a 
low outlet temperature can reduce agglomeration, as shown by the  study of Mohajel et al. 
using polymer based NPs as dry powder to deliver DNA, where it was found that using a low 
outlet temperature reduced the risk of DNA denaturation and decreased particle aggregation  
(Mohajel et al. 2012).   
It was found that operational parameters such as feed rate, aspirator capacity, atomised air flow, 
spray drying inlet and outlet temperature have a significant impact on recovered particle size 
and yield % of dry powders (Rohani et al. 2014a). The highest yield % of level 2 was relying 
on operation parameters (Table 5–1), Alfagih et al. had optimised for the spray drying process 
of PGA-co-PDL NPs using BSA a model protein incorporated into NCMPs for pulmonary 
delivery. It was found that flow rate was the most significant factor that had an effect on yield 
(Alfagih et al. 2015). Technically, during the spray drying process atomized air was used which 
should penetrate the liquid stream. However, if there was insufficient atomized air due to low 
feed rate, the dry powder sticks on the drying chambers and cannot be collected adequately     
(Motlekar and Youan 2008).  
A similar observation was noted in level 2 inlet 70 °C and outlet 47 °C temperature (Table 5–
1). It was found that the inlet temperature used in level 2 had affected the recovered NPs particle 
size and yield. Comparing the inlet temperature in level 1 and level 2 (Table 5–1) showed an 
increase from 45 °C to 70 °C. This inlet temperature  increase can lead to a reduction in the 
drying time and can inhibit particle aggregation (Mohajel et al. 2012). In addition, the high 
inlet temperature can lead to a decrease of residual moisture by enhancing water evaporation 
which cause less particles to stick in drying chamber walls  (Billon et al. 2000). However, high 
inlet temperature may affect the small nucleic acids stability (Mohajel et al. 2012).  
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5.5.2 Water content and flowability  
Table 5–4 showed the water contents for all the formulations, which were within the spray 
dried powder range. However, F4 had the lowest moisture content, due to a higher percentage 
of mannitol (Jensen et al. 2012). Adding mannitol as an excipient enabled the formulation to 
have less water content, and the powder with the least water content reduces the cohesion 
between particles and therefore increases the powder respirability (Chew and Chan 2002). 
Mannitol has hygroscopic properties enabling the formation of hydrogen bonds with water 
molecules causing water replacement which stabilises the formulation (Clegg et al. 1982, 
Schüle et al. 2008, Sarmento et al. 2006). The high water content may also have a negative 
impact on product stability (You et al. 2007), however by keeping the water content low it is 
likely to result in high storage stability.  Adi et al.  reported that the presence of mannitol in 
spray dried powder reduced water content, which prevented powder recrystallization, where 
the mannitol is thought to have decreased the amount of water bound in spray dried powder 
(Adi et al. 2010). 
As a consequence, adding mannitol to the formulation was successful and kept moisture 
content low, and the optimum ratio of L-leucine to mannitol F4; 25:75, (Table 5–3) was also 
shown to have an effect on water content, which is in accordance with other studies   (Li et al. 
2016b, Chow et al. 2017). Additional research showed that mannitol used in a combination 
with amino acid (L-alanine), a study by Rohani et al. found that the formulation containing 
mannitol and amino acid had a moisture content range between 4 – 6 % (Rohani et al. 2014b) 
compared to our results  2.02±0.03 % – 5.1±0.37 % (Table 5–4). Mannitol is a commonly-used 
excipient in spray drying powders which has a good safety record, which produces NCMPs 
that are compatible, dissolve easily in lung fluid and has regulatory approval (Jensen et al. 
2010, Pilcer and Amighi 2010, Burness and Keating 2012).     
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The NCMPs’ flowability was determined by Carr’s index, which showed F4 formulation has 
poor powder flow 33.30 % (more than 25 %).  This property could be due to powder 
aggregation and the particles could not re-form again. Due to the limited mass of powder, larger 
volume cylinders could not be used, hence a 5 ml measuring cylinder was used instead. This is 
not ideal and may have resulted in poor flow as determined by Carr’s index as this is associated 
with narrow cylinder during tapping that does not allow the powder particles to flow thus they 
become compact and restricted in movement. The F4’s poor powder flow, could be due to 
powder adherence to walls of measuring cylinder compared to other formulation resulted due 
to strong van der Waal force between particles  (Tawfeek et al. 2011). Similar results were 
reported by Alfagih et al. when PGA-co-PDL NPs-NCMPs were used and leucine as an 
excipient, where they found high Carr’s index values and poor powder flowability (Alfagih et 
al. 2015).   However, inhalation of the NCMPs with mannitol and leucine, will results in 
dissolution of the excipients in lung lining fluid, subsequently releasing NPs for uptake by lung 
cells.  NCMPs composed of PLGA NPs and mannitol have been shown to decompose in the 
lung lining fluid and release NPs (Jensen et al. 2010).  
5.5.3 In vitro aerosolisation studies  
Incorporation of L-leucine into the formulations improved both FPF % and FPD. By adding 
leucine to the spray dried formulation, the aerosolisation performance was impacted (Tawfeek 
et al. 2011). F4 of optimum condition containing leucine had the highest FPF ratio 51.33±2.9 % 
(Fig 5–2A), which indicated it had the best aerosolisation properties and improved 
aerosolisation performance (Rabbani and Seville 2005, Li et al. 2005, Seville et al. 2007, Sou 
et al. 2013, Lucas et al. 1999). Thus, adding leucine to the spray dried formulation had a 
positive  impact on the aerosolisation performance (Tawfeek et al. 2011).  
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Adding L-leucine to spray dried powders reduces the forces of attraction due to less contact 
points between particles forming rough particle surface and lower spray dried powder 
aggregation which causes greater dispersibility. This property also affects the shape of spray 
dried powders which will be discussed further in section 5.5.4. Furthermore, the L-leucine 
amount in the spray dried powder has an effect on aerosolisation performance, comparing 
FPF % of F4 and F5 as L-leucine ratio in F4 (25 % L-leucine) was higher than F5 (0 % L-
leucine), difference was observed where, F4 had FPF %, 51.33±2.9 % and F5 had FPF %, 
19.96±1.2 % (Fig 5–2A). This difference was  due to less powder stickiness and cohesiveness, 
which is in line with another study conducted by Gervelas et al. when leucine was added to 
spray dried powder, and it was found that the higher leucine concentration in the formulation 
the better aerosolisation performance (Gervelas et al. 2007).  
As seen in Fig 5–2B, the MMAD results showed that F1-F4 were less than 6 µm whereas, F5 
was 6.03±1.08 µm. The difference here suggests excipient influences MMAD, F1-F4 had 
mannitol percentage of less than F5. A study by Jensen et al. showed that spray dried NPs with 
high concentration mannitol resulted in higher MMAD compared with spray dried NPs with 
lower mannitol (Jensen et al. 2010). The amount of mannitol in formulation and absent of L-
leucine may form aggregated powders and a rougher surface which contributes to higher 
MMAD. Kaialy and Nokhodchi used mannitol as excipient in spray dried powder, and they 
found that the presence of a high mannitol concentration in the formulation increased MMAD, 
and that was reflected by powder cohesive force  aggregation (Kaialy and Nokhodchi 2013).  
Another reason for the difference between F1-F4 and F5 MMAD, was due to F5 had no L-
leucine and 100 % concentration of mannitol, and it was observed that there was a decrease in 
FPF % and an increase in MMAD > 6 µm. Similar results were obtained by Chow et al. when 
various concentrations of L-leucine were used with mannitol in inhaled powder formulation, 
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and they found that absence of L-leucine in powder reduced FPF % and increased MMAD 
(Chow et al. 2017).   
The MMAD values were less than 6 µm, which means within the range of 1 – 5 µm, is 
necessary for it to be deposited in the middle to deep lung regions by sedimentation due to 
gravity (Carvalho et al. 2011b), whereas those particles with MMAD of more than 6 µm are 
considered to deposit in the upper conducting airways  (Carvalho et al. 2011a). Although F4 
MMAD is within 1 – 5 µm, the deposition profile from NGI data showed that 20 % of the 
formulation deposited in NGI stage is less than 5 µm. This can predict the amount of miR-146a 
that will be deposited in the regions of the lungs and have potential cell uptake, and can also 
produce change in targeted gene expression as shown in section 5.4.6.  
The FPF, ED, and MMAD values obtained  would suggest very good aerosolisation properties 
and a deep lung deposition profile which is in agreement with other studies that used PGA-co-
PDL NPs-NCMPs  (Kunda et al. 2013).  Hence, NCMPs when inhaled, L-leucine and mannitol 
will dissolve the lung lining fluid, subsequently releasing miR-146a-NPs to be taken up by lung 
cells and cause the required biological expression. This mechanism was also proposed by 
Kunda et al. and Alfagih et al. (Kunda et al. 2014b, Alfagih et al. 2015).  
5.5.4 Morphology, yield and recovered NPs particle size 
The surface morphology of NCMPs was carried out using SEM, and the micrographs showed 
that NCMPs were corrugated, which suggested this shape was due to the reduction in the 
cohesion between particles  (Chew et al. 2005b, Chew and Chan 2001). This occurred due to 
water evaporation that happened during the spray drying process causing high vapour pressure. 
In addition, the presence of L-leucine in spray-dried particles, which has low density was 
capable of forming space thereby filling and packing particle’s structure (Sou et al. 2013, 
Alfagih et al. 2015, Lucas et al. 1999). These corrugated surface particles would have a larger 
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surface area, leading to an increase in the particles’ capability to diffuse and disperse in lung 
fluid thus releasing miR-146a-NPs.  The formulation was more controlled by choosing sugar 
excipient such as mannitol rather than lactose, which interacts with certain amine groups and 
affect the particle’s morphology (Vehring 2008, Bharate et al. 2016).  
Analysis of F4, produced a high yield 86.05±15.01 (Table 5–5) of dry powder accompanied 
with the desired small particle size recovery < 500 nm. The high yield was due to reduced loss 
of dry powder during the collection process which also affected on recovered particle size that 
relies on centrifugal forces for collection of final dry powder due effective separation capacity 
of cyclone. Another reason for producing a high yield is that the spray dryer used (section 
5.3.2) in preparing spray dried powder can produce high yield, when the process and 
formulation parameters e,g flow rate, inlet temperature, atomized air flow, aspiratory capacity 
undergo appropriate optimisation (Motlekar and Youan 2008, Sosnik and Seremeta 2015).  
Hence, F4 was chosen as optimum to use level 2 parameters. There was an inverse correlation 
observed between increased mannitol concentration and yields. The increase of mannitol 
concentration lead to an increase in particle size from 244.8±4.4 nm before spray drying 
(Section 3.4.2) to 409.7±10.05 nm (Table 5–5) and 327.96 nm (Table 5–3) after spray drying. 
This particle size increase after spray drying may be a result of change in the conformation 
under operating conditions of spray drying, and similar results were also found by Sham et al.  
for spray dried powder prepared with sugar as excipient for gelatine NPs, and the size after 
spray drying which were in nano-sized (Sham et al. 2004).  
The NCMPs’ yield obtained a good production yield for all the formulations. However, spray-
dried microparticles’ yield was changeable and affected by the ratio of excipients. When the 
optimum parameters were applied with no mannitol, there was a lesser yield % (64 %). The 
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optimum parameters used for the production of the  highest yield % of dry powder resulted in 
reasonable yield  of NCMPs 86.0±15.01 % (Table 5–5) (Jensen et al. 2010).  
F4 was chosen as the optimum formulation despite its poor flowability comparing to F3 that 
had showed better flow character, (Table 5–4) but the recovered NPs’ size of F3 was almost 1 
µm (823.13 nm), (Table 5–3) which was too large. Alfagih  et al. have obtained results with 
poor flowability when added leucine to NCMPs but managed to achieve a significantly higher 
FPF % and the smallest recovered particle size (Alfagih et al. 2015). As mentioned above, F4 
was selected as the optimum formulation according to the high yield, lower moisture content, 
good aerosol properties and the recovered NPs’ size which was similar to the starting NPs’ size 
(Table 5–5). It can be noted from Tables 5–2 and 5–4 the NCMPs reported here have high yield 
values, which indicate the significant potential of using a mixture of mannitol and L-leucine 
properly, with effective parameters. However, the yield values reported in previous studies 
were to be from 40 – 50 % (Alfagih et al. 2015, Tawfeek et al. 2011, Kunda et al. 2015a). 
Therefore, the prepared formulation would effectively deliver the small nucleic acid to the lung 
as inhaled dry powder.  
5.5.5 Impact of miR-146a on target expression 
 The miR-146a-NCMPs lowered expression of t target genes IRAK1 and TRAF6. As shown in 
Fig. 5–4 that miR-146a activity was maintained after spray drying, indicating the ability of 
miR-146a-NCMPs. There were different apparent sensitivities of IRAK1 and TRAF6 to the 
miR-146a-NCMPs, where TRAF6 was significantly reduced with a relatively low dose due to 
miR-146a-binding sites in their 3'UTR. This suggests that the dry powder particles combining 
amino acid and sugar did not affect the miR-146a silencing activity despite aggregation of 
recovered NPs and also protected biological activity of miR-146a.  
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 Immunoblotting (Fig. 5–5) supports that miR-146a activity was maintained after spray drying,  
with protein level changes after 24 h and 48 h of miR-146a-NCMPs’ treatment occurring in a 
dose dependent manner. Despite nucleic acid being exposed to high temperatures of 47 ˚C 
during the drying process, and the use of the delivery formulation and excipients, the biological 
activity of miR-146a appears to have been preserved.   
It appears that NCMPs delivered miR146a to site of action, and produced the required gene 
knockdown by inhibiting IRAK1 and TRAF6 genes, which is in  line with other studies that 
indicated miR-146a role in inhibiting expression of IRAK1 and TRAF6 genes (Taganov et al. 
2006). The local pulmonary delivery of miR-146a had played important role by targeting 
multiple genes after inhalation the dose that spread over various parts in lung (Rossi 2009, He 
et al. 2005, Bhardwaj et al. 2009). In fact, various studies have investigated siRNA and DNA 
delivery intended for inhalation (Jensen et al. 2010, Liang et al. 2015, Liang et al. 2014), but 
limited research has been performed on miRNA pulmonary delivery. The miRNA-based 
therapy has showed interesting progress for treating different diseases, the MRX34 using miR-
34 hepatocellular carcinoma and lung cancer have entered phase I clinical trials (Beg et al. 
2015). In addition, miRagen using miR-29 to treat pulmonary fibrosis, through intravenous 
injection in vivo has reached the pre-clinical studies (Montgomery et al. 2014). Therefore, the 
current study provides the feasibility of using miR-146a-NCMPs for therapeutic purposes as 
pulmonary drug delivery that manages COPD rather than other medications. 
5.6 Conclusion  
The results indicated that the method has been optimised for the spray drying of NCMPs. The 
selected PGA-co-PDL NPs were incorporated into L-leucine and mannitol as a carrier to 
improve the powder’s aerosolisation properties. Five different formulations were prepared with 
various excipients ratios.  
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The NPs’ size has been recovered after spray drying (409.7±10.05 nm) and geometric particle 
size is suitable for targeting the respiratory bronchiole. Moreover, the optimum formulation 
had a high yield (86.0±15.01 %), and low moisture content (2.02±0.03 %) which is essential 
for powder aerosolization and formulation stability. The aerosolization performance showed 
high FPF 51.33±2.9 %. The biological activity of miR-146a persevered after spray drying 
process and miR-146a loaded NCMPs caused gene silencing.   
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6.General Discussion  
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6.1 Overview  
 
Chronic obstructive pulmonary disease COPD is heterogeneous inflammatory disease and is a 
major cause of morbidity and higher mortality rates throughout the world. COPD is currently 
the fourth leading cause of death in the world and is predicted to become the third leading cause 
of chronic illness and death worldwide by 2030 (World Health statistics 2008). The current 
therapeutic strategies including pharmacological and non-pharmacological treatments for 
COPD have not been shown to delay and correct the long-term defects in lung function (Global 
Strategy for the Diagnosis, Management and Prevention of COPD and GOLD 2016).  
However, the expression of small non-coding RNA molecules known, as microRNAs 
(miRNAs) has been associated with neoplastic and inflammatory lung disease. Recent work 
suggests cytokine-dependent induction of miR-146a is impaired in COPD fibroblasts, leading 
to overexpression of cyclooxygenase (COX)-2 and enhanced production of PGE2 (Sato et al. 
2010). miR-146a is capable of controlling the Toll-like receptor and cytokine signalling 
through negative feedback regulation, associated with down regulation of IRAK1 and TRAF6 
protein levels (Taganov et al. 2006, Nahid et al. 2009).   
The ideal route of the pulmonary delivery of nucleic acid is non-invasive and offers various 
advantages over the more conventional oral, buccal, transdermal and nasal routes. miRNA can 
be administered in reduced doses for lung cell targeting, avoiding degradation by serum, and 
bypass of the first hepatic metabolism (Patton and Byron 2007, Takei et al. 2004) 
The promise of RNA interference mediated miRNA has provided a novel strategy to formulate 
non-viral intracellular carriers to knock down target messenger RNA (mRNA). Various studies 
have investigated the delivery of siRNA and DNA to target lung cells (Takashima et al. 2007, 
Jensen et al. 2010, Cherng et al. 1997, Andersen et al. 2008) but there is a very limited research 
has been investigated on miRNA delivery, which has the benefit of being able to regulate and 
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inhibit protein expression without interfering with other proteins. The aim of this project was 
to formulate and characterise miRNA containing NPs formulated as an inhalable dry powder 
microcarrier for the treatment Chronic Obstructive Pulmonary Disease (COPD). 
6.2 Optimisation of cationic nanoparticles 
 
The NPs size and surface charge play an important role in interaction with intracellular and 
extracellular components of cells. The interaction between the positive NPs charge and the 
negative cellular charge help in the particle uptake (Borm et al. 2006). Incorporation of DOTAP 
to NPs during NPs preparation methods was successful and produced cationic NPs. The use of 
DOTAP to produce cationic material have been previously explored, resulting in modified 
particle size and charge (Kumar et al. 2004, Jensen et al. 2012) 
It was found that DOTAP concentrations affected particle size and charge, the increase of 
DOTAP concentration reduced the particle size and increased surface charge to a more positive 
value. Similar results were reported by Kunda et al. when DMAB was used as a cationic 
surfactant, to prepare positively charged PGA-co-PDL NPs. They found that polymeric NPs 
have the ability to combine with other cationic compounds (Kunda et al. 2014b). The particle 
size decreased when the concentration of DOTAP increased to 30 mg/ml DOTAP (15 % w/v). 
The decrease of particle size has been associated with the ability of cationic material to reduce 
the interfacial tension between particle surface and aqueous phase, as well as DOTAP 
properties to restrain the enlargement of polymeric NPs (Song et al. 2006a, Jensen et al. 2012).  
When DOTAP incorporation to NPs applied for the preparation of cationic NPs, the adsorption 
of miR-146a occurred. The optimum adsorption condition and parameters on surface has ability 
to protect miR-146a over encapsulation, due to preventing from contact with solvent, 
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sonication and mechanical stress used during NPs preparation process (Cun et al. 2010, 
Soutschek et al. 2004).  
The positive charge formed on the NPs allowed the negatively charged miR-146a  for 
electrostatic interaction (Li et al. 2014). The adsorption of negatively charged miR-146a on the 
cationic NPs slightly decreased the surface charge. The cationic NPs charge remained positive 
after the miR-146a adsorption, the maximum level of miR146a adsorption was after 2 h, 
suggesting the saturation time, which help in effective ability to bind to anionic cell surface 
(Yuba et al. 2008).  
6.3 Spray drying of miRNA-containing NPs into NCMPs 
 
Spray drying has been shown to be a potential technique for small nucleic acids intended for 
inhalation with the use of excipients such as mannitol, trehalose, L-leucine and lactose alone 
or in combination (Jensen et al. 2010, Takashima et al. 2007, YT Chow and KW Lam 2015). 
The spray drying optimisation process was used to incorporate NPs into NCMPs using a mix 
of L-leucine and mannitol excipients. The optimum level 2 produced highest yield percentage 
96.00 % and smallest recovered particle size. 
 It was noted that the operational parameters such as feed rate, spray drying inlet, outlet, 
aspirator capacity, and atomised airflow have a significant effect on the yield and recovered 
particle size. Rohani et al. have optimised spray dry powder intended for pulmonary delivery, 
they found that the processing parameters affected particle size and achieved high yield  
(Rohani et al. 2014a). Others reported similar observations (Alfagih et al. 2015, Motlekar and 
Youan 2008, Mohajel et al. 2012, Billon et al. 2000). 
 The NPs were successfully spray dried using a mix of L-leucine and mannitol. The NCMPs 
showed a corrugated surface shape this occurred due to the reduction in cohesion between 
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particles, water evaporation that happened during spray drying process causing high vapour 
pressure. In addition, the presence of L-leucine in spray-dried particle, which has low density 
was capable of forming space filling thereby and packed particle structure (Chew et al. 2005b, 
Lucas et al. 1999, Sou et al. 2013, Alfagih et al. 2015).   
Moreover, the NCMPs formulations produced high values of FPF % and FPD. This could be 
attributed to L-leucine excipient in the formulation, which improved aerosolisation 
performance (Kunda et al. 2014b, Tawfeek et al. 2011, Li et al. 2005). FPF, ED, MMAD values 
would suggest very good aerosolisation properties that should allow NCMPs formulation to 
deposit in the middle to deep lung regions.  
Others reported similar results when L-leucine was used in the formulation (Kunda et al. 2013, 
Alfagih et al. 2015, Kunda et al. 2014b). The NCMPs formulation has low moisture content, 
which reflects the efficient spray drying conditions performed leading to helping in powder 
storage. This provides an indication of the use of mannitol as an excipient in the formulation 
that increases the powder respirability (Chew and Chan 2002). Therefore, the optimum spray 
dried parameters   achieved high yield good recovery of NPs and maintained miRNA 
functionality.  
6.4 The biological activity of miR-146a  
The highest miR-146a loaded NPs concentration showed a reduction in target gene IRAK1 
expression to 40 %. While, target genes TRAF6 were determined and the lowest NPs 
concentration caused reduction in expression to over 20 %. The miR-146a showed activity as 
a negative regulator of inflammation by inhibiting the expression of IRAK1 and TRAF6 genes 
(Taganov et al. 2006). Another a study by Zhao et al. showed miR-146a implicated as a 
negative feedback regulator of NF-кB and important component of immune cell gene 
regulation (Zhao et al. 2011).  
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 In addition, the miR-146a-NPs affected IRAK1 protein levels, and decreased the protein levels. 
This suggest that miR-146a released in the cell successfully targets IRAK1 mRNA, and leads 
to translational repression (Kuhn and Joshua-Tor 2013). These results show the promising NPs 
delivery carrier, protecting miR-146a from degradation and enzymatic activity in the lung 
airways  (Lam et al. 2015, Yuba et al. 2008). Similar results were reported by Liang et al. they 
showed that polymer based NPs used as carrier to deliver miR-26a to HepG2 cells  (Liang et 
al. 2011).  
The miR146a biological activity maintained after spray drying. The miR-146a-NCMPs 
knockdown the targeted IRAK1 and TRAF6 genes, accompanied with protein level changes in 
a dose dependent manner. This could be attributed to the appropriate use of the delivery 
formulation and excipients   (Jensen et al. 2010, Liang et al. 2015).  
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7. Future work 
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7.1 Future work  
Further studies will evaluate the biological studies of miR-146a in terms of pro-inflammatory 
cytokine such as pIL-8 and TNF-α.  ELISA assay indicate the measurement of  pIL-8 promoter- 
GFP reporter protein level  (MacKenzie et al. 2001). The optimum miR-146a-NPs incorporated 
NCMPs which would be helpful to examine the biochemical response, as well as the activity 
and stability of miR146a. To further expand the delivery potential of miR-146a-NCMPs for in 
vivo applications the promising in vitro studies need to move to animal models. The best 
experimental animal models for miR-146a-NCMPs administrated via inhalation for COPD 
studies are mice, guinea pigs and rats (Ghorani et al. 2017).  
 The stability of NCMPs will be determined using X-ray powder diffraction and differential 
scanning calorimeter (DSC) to evaluate changes in the crystallinity of the particles. Further 
studies should also examine the long-term stability of NCMPs at various temperature and 
humidity conditions. 
Further immunoblotting studies will also evaluate the effect of miR-146a-NPs/NCMPs on 
protein expression of TRAF6. If these results could be acquired in addition to the obtained 
findings that showed the effect of miR-146a-NPs/NCMPs on target genes and protein 
expression of IRAK1, this will help provide full insight into miR-146a-NPs/NCMPs biological 
function activity. Further optimised studies to evaluate luciferase reporter, monitor the 
transfection and interaction with 3’UTR miRNA and determine the expression effect of miR-
146a-NPs.  
miR-146a regulate Toll-like receptor (TLR) biological signalling through interleukin-1 
receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6). 
However, there are likely to be other targets for miR-146a (Taganov et al. 2006). Transcriptome 
analyses will enable large-scale identification genes modulated by miR-146a-NCMPs.  
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The delivery of miRNAs offer an exciting field for NPs, inhalation and inflammatory diseases. 
There are various studies in literature linked to miRNAs role being used as biomarkers for 
diagnosis and regulation. This highlight the importance of miRNAs to be useful and reach the 
clinical trial stage. The significant therapeutic action of miRNA mimics enabled miR-34 to be 
used for the treatment of many cancers such as;  colon, ovarian, cervical, non-small cell lung 
cancer, and hepatocellular carcinoma, and miR-34 has been tested in phase I clinical trials 
(Bouchie 2013b).  
In order to align the present work to the pre-existing literature, the cationic DOTAP was 
successfully used to produce cationic NPs that offer positive surface charge for miR-146a 
adsorption. The selected PGA-co-PDL NPs were incorporated into L-leucine and mannitol as 
a carrier to improve the powder’s aerosolisation properties. The biological activity of miR-
146a persevered after spray drying process and miR-146a loaded NCMPs caused gene 
silencing. The use of polymeric NPs/ NCMPs in the delivery of miR-146a to lung cells offers 
important therapeutic potential to cellular dysregulations with less off-target effects. However, 
taking into account the advantage of the promising biological effects of inhaled siRNA in the 
lung there has been very limited work exploring miRNA spray drying. In the field of COPD 
and inhaled miRNA there is need of more future work to be done of using more miRNA spray 
drying due to their therapeutic potential as pulmonary drug delivery that manages COPD rather 
than other medications. 
 
It is important to take into consideration, the practical considerations of patient compliance 
with repeated doses and the probability of using combination of miR-146a-NCMPs with other 
chemotherapy or immunotherapy. In the future, NPs containing miR-146a will gain importance 
in lung diseases and other human disease. 
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Appendices  
 
 
 
Appendix–1. Effect of miR-146a loaded NPs on IRAK1 expression. Data of all concentrations 
were pooled from three independent experiments. The expression of IRAK1 was normalised 
to GAPDH expression. Values are Mean ± SD (n=3). 
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Appendix–2. Effect of miR-146a loaded NPs on TRAF6 expression. Data of all concentrations 
were pooled from three independent experiments. The expression of TRAF6 was normalised 
to GAPDH expression. Values are Mean ± SD (n=3). 
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